

CURRICULUM VITAE

ERVIN STEVE WOODLE, M.D., F. A. C. S.

OFFICE ADDRESS Division of Transplantation
Department of Surgery
University of Cincinnati
College of Medicine
231 Bethesda Avenue
Room 2455 A, ML 0558
Cincinnati, Ohio 45267-0558

Phone (513)-558-6001
Fax (513)-558-7040
Email woodlees@uc.edu

DEGREES

1976 Bachelor of Science (Summa cum Laude)
Texas A&M University

1980 Doctor of Medicine (Magna cum Laude)
University of Texas Medical Branch at Galveston

INTERNSHIP

1980-1981 General Surgery
University of Texas Health Science Center at Houston

RESIDENCY

1981-1982 General Surgery
University of Texas Health Science Center at Houston

1984-1986 General Surgery
University of California, Davis

1986-1987 Chief Resident in General Surgery
University of California Davis

CLINICAL FELLOWSHIPS

1987-1988 Fellow in Renal and Pancreatic Transplantation
Department of Surgery

University of Chicago

1988 Fellow in Hepatic Transplantation and Hepatobiliary Surgery
Department of Surgery
University of Chicago

RESEARCH FELLOWSHIPS

1982-1984 NIH Surgical Research Fellow
Department of Surgery
University of California, Davis

1988-1990 NIH Surgical Research Fellow
Focus: Transplantation Immunology
Preceptor: Jeffrey A. Bluestone, Ph.D.
Department of Surgery/Committee on Immunology
University of Chicago

ACADEMIC APPOINTMENTS

1990 - 1992 Assistant Professor of Surgery
Section of Organ Transplantation
Department of Surgery
Washington University School of Medicine
St. Louis, Missouri

1992 - 1998 Assistant Professor of Surgery and Immunology
Section of Organ Transplantation
Department of Surgery
University of Chicago Pritzker School of Medicine
Chicago, Illinois

1998 - 1999 Associate Professor of Surgery and Immunology
Section of Organ Transplantation
Department of Surgery
University of Chicago Pritzker School of Medicine
Chicago, Illinois

1992 – 1999 Committee on Immunology
University of Chicago Pritzker School of Medicine
Division of Biological Sciences
Chicago, Illinois

1992 - 1999 Director, Renal Transplantation
University of Chicago

1999- present Professor of Surgery
University of Cincinnati
College of Medicine

Cincinnati, Ohio

1999- present	Director, Division of Transplantation Department of Surgery University of Cincinnati College of Medicine Cincinnati, Ohio
1999- present	Director of Renal Transplantation University of Cincinnati College of Medicine Cincinnati, Ohio
1999- present	Director of Pancreas Transplantation University of Cincinnati College of Medicine Cincinnati, Ohio
1999-2001	Director Israel Penn International Transplant Tumor Registry University of Cincinnati College of Medicine Cincinnati, Ohio
2001- present	Chairman, Board of Directors Israel Penn International Transplant Tumor Registry University of Cincinnati College of Medicine Cincinnati, Ohio
2001-present	Director of Liver Transplantation University of Cincinnati College of Medicine Cincinnati, Ohio

HOSPITAL APPOINTMENTS

1990 - 1992	Barnes Hospital
1990 - 1992	St. Louis Children's Hospital
1990 - 1992	St. Louis Regional Medical Center
1990 - 1992	Veterans Administration Hospital in St. Louis
1992 – 1999	University of Chicago Hospitals
1992 – 1999	Wyler Children's Hospital, Chicago, Illinois
1999-present	University of Cincinnati Hospitals
1999-present	Cincinnati Children's Hospital
1999-present	Christ Hospital, Cincinnati, Ohio
1999-present	Deaconess Hospital, Cincinnati, Ohio
1999-present	Jewish Hospital, Cincinnati, Ohio

OPO POSITIONS

1999-present	President, Ohio Valley LifeCenter OPO
--------------	---------------------------------------

LICENSURE

Texas	# F-7325
California	# C-040707
Illinois	# 036-075359
Missouri	# R3N79
Ohio	#77349

BOARD CERTIFICATION

1988	American Board of Surgery #33328 Expires March 23, 1998
1995	American Board of Surgery Recertification #044098 Expires March 23, 2008

HONORS AND AWARDS

Eagle Scout with Bronze Palm`	1969
Undergraduate	
Phi Theta Kappa Honor Society	1973
Faculty Award Scholarship	1973
Who's Who in American Junior Colleges	1973
Distinguished Student	1975/1976
Edgar Rack Memorial Scholarship	1975
Phi Kappa Phi Honor Society	1976
Graduated <u>Summa Cum Laude</u>	1976

Medical School

Alpha Omega Alpha (Junior Year)	1979
Mu Delta Honorary Medical Society	1979
Dr. Walter Junius Hildebrand Scholarship	1979
Edward Randall Medal for Academic Excellence (<i>High Score, Part I, National Board Exams</i>)	1978
Edward Randall Medal for Academic Excellence (<i>High Score, Part II, National Board Exams</i>)	1979
Hambrock-McGarity Award for Outstanding Student in Obstetrics and Gynecology	1979
Herman Barnett Award for Outstanding Student in Surgery and Anesthesia	1980
Graduated <u>Magna Cum Laude</u> (<i>Rank - 4th in Class of 208</i>)	1980

Post Graduate

<i>Who's Who in Science and Engineering</i>	1995
<i>Who's Who in America</i>	1996
<i>Who's Who in Medicine and Healthcare</i>	1996
<i>Who's Who in the World</i>	1996
<i>Who's Who in America</i>	1997
<i>Who's Who in the Midwest</i>	1997
<i>Who's Who in the World</i>	2000

RESEARCH AWARDS - CAREER DEVELOPMENT

American Heart Association Clinician Scientist Award	1992-1996
--	-----------

NIH STUDY SECTIONS/STEERING COMMITTEES

National Institute of Allergy and Infectious Disease Special Emphasis Panel ZAI1 -KMC-I-O16K Cooperative Clinical Trials in Adult Transplantation (CCTAT)	1996
National Institute of Health Steering Committees NIH/NCCR Steering Committee for Islet Transplantation Resource Centers	2001

MEDICAL AND ACADEMIC SOCIETIES

American Association for the Advancement of Science
 American Association for the Study of Liver Diseases
 American Association of Immunologists

American College of Surgeons
 American Society of Transplant Physicians
 American Society of Transplant Surgeons
 Association for Academic Surgery
 Cell Transplant Society
 Central Surgical Association
 Chicago Association of Immunologists
 Chicago Surgical Society
 Clinical Immunology Society
 The Erlanger Society
 Illinois Surgical Society
 International College of Surgeons
 International Liver Transplantation Society
 International Xenotransplantation Association of the Transplantation
 Society
 National Kidney Foundation, Medical Advisory Board
 Society of Nuclear Medicine
 Society for Organ Sharing
 Society of University Surgeons
 St. Louis Surgical Society
 Stanley J. Dudrick Surgical Society
 The Transplantation Society
 Western Surgical Association
 Earl F. Wolfman Surgical Society
 Academy of Medicine of Cincinnati
 The Cincinnati Surgical Society

EDITORIAL REVIEW BOARDS

Clinical Nephrology
 Graft
 Investigative Drugs
 Transplantation

EDITORIAL REVIEW (ad hoc)

American Journal of Kidney Diseases
 American Journal of Transplantation
 Human Immunology
 International Immunology
 Journal of Clinical Investigation
 Journal of Immunology
 Journal of Surgical Research
 Journal of Vascular and Interventional Radiology
 Journal of Vascular Surgery
 Lancet
 Nature Biotechnology
 Surgery

Transplantation
World Journal of Surgery

ACADEMIC COMMITTEES

Faculty Subcommittee for Institutional Self-Study: Liaison Committee on Medical Education Washington University School of Medicine	1990-1992
Research Committee, Department of Surgery University of Chicago	1993-1999

COMMITTEES: PROFESSIONAL SOCIETY AND ORGANIZATIONS

Member Scientific Studies Committee American Society of Transplant Physicians	1995
Chairperson Scientific Studies Committee American Society of Transplant Physicians	1996-1999
Member Kidney Pancreas Transplantation Committee American Society of Transplant Physicians	1995
Co-Chairperson Kidney-Pancreas Transplantation Committee American Society of Transplant Physicians	1996-1997
Chairperson Kidney-Pancreas Transplantation Committee American Society of Transplant Physicians	1997-1998
Member Program and Publications Committee American Society of Transplant Physicians	1996-1998
Co-Chairperson Program and Publications Committee Liver/Intraabdominal Section	1996-1997
Chairperson Program and Publications Committee Liver/Intraabdominal Section	1997-1998
Member Nominations Committee American Society of Transplant Physicians	1996-present

Member	Program and Publications Committee American Society of Transplant Surgeons	1997-2000
Member	Continuing Medical Education Committee American Society of Transplant Surgeons	1997-2000
Chairperson	Liver-Intraabdominal Subcommittee Program Committee American Society of Transplant Physicians	1997-1998
Administrative Chairperson	Joint ASTP/ASTS Scientific Studies Subcommittee on Corticosteroid Withdrawal	1997
Administrative Chairperson	Joint ASTP/ASTS Scientific Studies Subcommittee on Posttransplant Lymphoproliferative Disorders	1997
Administrative Chairperson	Joint ASTP/ASTS Scientific Studies Subcommittee on Immunosuppressive Drug Therapy Outcomes	1997
Member	ASTP/ASTS Joint Task Force on Tolerance	1997-1998
Councillor	ASTP Board of Directors American Society of Transplant Physicians	1998
Member	United Network for Organ Sharing (UNOS) Scientific Advisory Committee	1998
Member	United Network for Organ Sharing (UNOS) Tumor Registry Scientific Advisory Committee	1998
Member	Regional Organ Bank of Illinois (ROBI) Human Research Subcommittee	1998
Member	American Society of Transplantation	

Public Policy Committee 1999-2003

Member

Ohio Solid Organ Transplantation Consortium
Pancreas/Islet Patient Selection Subcommittee 2000

Member

Board of Directors
Ohio State Consortium on Solid Organ Transplantation 2001-present

Member

Liver Transplantation Committee
Ohio State Consortium on Solid Organ Transplantation 2001-present

Member

Pancreas/Islet Transplantation Committee
Ohio State Consortium on Solid Organ Transplantation 2001-present

Member

Kidney Transplantation Committee
Ohio State Consortium on Solid Organ Transplantation 2001-present

Chairperson

Artificial Liver Support; Hepatocyte Transplantation Abstract Review
Group
American Association For The Study of Liver Disease 2001-2002

HOSPITAL COMMITTEES

Operating Room Committee 1993-1999
University of Chicago

FEDERAL REGULATORY AGENCIES

Biological Response Modifiers Advisory Committee 1994 - 1997
Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration
Department of Health and Human Services

Immunosuppressant Drug Subcommittee of the Antiviral
Drugs Advisory Committee 1995-1998
Center for Drugs Evaluation (CDER)
Food and Drug Administration
Department of Health and Human Services
Ad Hoc Member

Xenotransplantation Subcommittee 1999
 Biological Response Modifiers Advisory Committee
 Center for Biologics Evaluation and Research (CBER)
 Food and Drug Administration
 Department of Health and Human Services

SCIENTIFIC ADVISORY BOARDS

SangStat Medical Corporation 1996

CORPORATE ADVISORY COMMITTEES

SangStat
 Thymoglobulin Clinical Trials
 Generic Cyclosporine Clinical Trials
 FDA Product License Application (PLA) for Thymoglobulin in the
 Treatment of Kidney Transplant Rejection

Wyeth/Ayerst
 Rapamycin Phase III Pivotal Study for Prevention of Renal Allograft
 Rejection
 RPSG₂ Advisory Board

Fujisawa
 FK506/MMF Dose Ranging Trial
 FK506/MMF Multicenter, Randomized Corticosteroid Withdrawal Trial
 Design Committee
 FDA Product License Application (PLA) for Tacrolimus in
 Renal Transplantation Rejection Prophylaxis

Biogen
 Anti-CD40 ligand antibody Advisory Board

Protein Design Labs
 Humanized Anti-CD3 antibody Advisory Board

NATIONAL ORGANIZATIONS: POSITIONS

Board President
 American Diabetes Association
 Cincinnati Chapter 2001-2002

Medical Advisory Board
 Kidney Foundation
 Cincinnati Chapter 2001-2002

VISITING PROFESSORSHIPS

- 1) University of Maryland January 7, 1997
- 2) Washington Hospital Medical Center February 26, 1997
- 3) Yonsei University, Seoul, South Korea September 23, 1997
- 4) University of Pennsylvania October 8, 1997
- 5) Harvard University, Massachusetts General Hospital December 3, 1997
- 6) Vanderbilt University December 5, 1997
- 7) Saint Barnabas Health Care System March 9-10, 1998
- 8) Georgetown University Medical Center June 30, 1999

RESEARCH SUPERVISION AND MENTORSHIP

Clinical Transplant Fellows

Dr. David C. Cronin
 Dr. Christopher Siegel
 Dr. George E. Loss
 Dr. Hani P. Grewal
 Dr. Joseph F. Buell
 Dr. Gregory Tiao
 Dr. Steven Potter

Present Position

Faculty, University of Chicago
 Faculty, Case Western Research University
 Faculty, Ochsner Clinic
 Faculty, University of Tennessee
 Faculty, University of Chicago
 Fellow, University of Cincinnati
 Fellow, John Hopkins Hospital

Research Fellows

Dr. Sanjay Kulkarni
 Dr. Adam Kopelan
 Dr. Jonathan Fisher
 Dr. Craig Turner

Resident, University of Chicago
 Resident, University of Chicago
 Resident, University of Chicago
 Resident, University of Chicago

College Students

Tsuyoshi Todo

Undergrad Student, University of Chicago

Clinical Pharmacists

Jeanne Mead, PharmD.
 Agnes Lo, PharmD.

Jennifer Trofe, PharmD.

Meredith Aull, PharmD.
 Robyn Boardman, PharmD.

Staff Pharmacist, University of Chicago Hospitals
 Clinical Research Pharmacist, University of Tennessee
 Clinical Research Pharmacist, University of Cincinnati
 Clinical Research Pharmacist, Cornell University
 Resident, University of Cincinnati

ORIGINAL ARTICLES

1. **Woodle ES**, Moody RR, Cox KL, Cannon RA, Ward RE: Orthotopic liver transplantation in a patient with Amanita poisoning. *Journal of the American Medical Association* 253: 69, 1984.
2. **Woodle ES**, Ward RE: Liver transplantation. *Western Journal of Medicine* 142: 539, 1985.
3. **Woodle ES**, Hunter GC, Ward RE: Diaphragmatic vena cava cuff in hepatic transplantation. *Transplantation* 40: 105, 1985.
4. Stadalnik RC, Vera DR, **Woodle ES**, Trudeau WR, Porter B, Ward RE, Krohn K, O'Grady L: Tc99m-NGA functional liver imaging: Preliminary clinical experience. *Journal of Nuclear Medicine* 26: 1233, 1985.
5. **Woodle ES**, Hunter GC, Ward RE: Orthotopic porcine liver transplantation: Operative technique. *Journal of Surgical Research* 34: 483, 1985
6. Porter BA, **Woodle ES**, Ward RE: Hepatic perfusion abnormalities after liver transplantation: Demonstration by angiography and computed tomography. *Cardiovascular and Interventional Radiology*, 8: 169, 1985.
7. Farias LR, **Woodle ES**, Hunter ES, Frey CF, Nakayama SI, Ward RE: A simple technique for experimental hepatic vein catheterization. *Laboratory Animal Science*, 36: 406, 1986.
8. Eisele P, **Woodle ES**, Hunter ES, Talken L, Ward RE: Anesthetic, preoperative considerations for liver transplantation in swine. *Laboratory Animal Sciences*, 36: 402, 1986.
9. **Woodle ES**, Vera DR, Ward RE, Stadalnik RC: Tc-NGA imaging in liver transplantation: Preclinical studies. *Surgery* 102: 55, 1987
10. Thistlethwaite JR, Stuart JK, Mayes JT, Gaber AO, **Woodle ES**, Buckingham MR, Stuart FP: Complications and monitoring of OKT3 therapy. *American Journal of Kidney Diseases* 11: 112, 1988.
11. Bartlett ST, **Woodle ES**, Hibler T, Ward RE: Stapled duodenal-cystic anastomosis in pancreas transplantation. *Transplantation* 46: 460, 1988.
12. **Woodle ES**, Heffron TG, Stuart JK, Thistlethwaite JR, Stuart FP: Effect of discontinuing or restricting cyclosporine on late renal allograft rejection and function. *Transplantation Proceedings* 21: 1641-1642, 1989.
13. Thistlethwaite JR, **Woodle ES**, Mayes JT, Stuart JK, Heffron TG, Spargo BH, Stuart FP: Aggressive needle biopsy prevents loss of post-transplant dysfunction. *Transplantation Proceedings* 21: 1890-1892, 1989.

14. Vogelbach P, Emond JC, Thistlethwaite JR, **Woodle ES**, Henry SB, Broelsch CE: Preservation of liver grafts with University of Wisconsin solution - preliminary results at the University of Chicago. *Langenbecks Archive Supp* 435-439, 1989.
15. **Woodle ES**, Ward RE, Stadalnik RC, Vera DR: Tc-NGA imaging in liver transplantation: clinical experience. *Surgery* 105: 401-407, 1989.
16. Emond JC, Whittington PF, Thistlethwaite JR, **Woodle ES**, Vogelbach P, Broelsch CE: Reduced-size liver transplantation as primary therapy in children with end-stage liver disease. *Proceedings of the Institute of Medicine* 42: 29, 1989.
17. Vera RE, **Woodle ES**, Stadalnik RC: Kinetic sensitivity of a receptor binding radiopharmaceutical (Tc-99m) Galactosyl-neoglycoalbumin. *Journal of Nuclear Medicine* 30: 1519-1530, 1989.
18. Broelsch CE, Vogelbach P, Emond JC, **Woodle ES**, Thistlethwaite JR, Aran P, Baker A: Shunt surgery in regards to indications for liver transplantation. *Langenbecks Archive Supp II* 293-299, 1989.
19. **Woodle ES**, Thistlethwaite JR, Emond JC, Whittington PF, Black DD, Aran PP, Baker AL, Stuart FP, Broelsch CE: OKT3 therapy for hepatic allograft rejection: Comparison of results in adults and children. *Transplantation Proceedings* 22: 1765, 1990.
20. Thistlethwaite JR, Emond JC, **Woodle ES**, Vogelbach P, Whittington PE, Broelsch CE: Increased utilization of organ donors: Transplantation of two recipients from single donor livers. *Transplantation Proceedings* 22: 1485, 1990.
21. Ellenhorn JDI, **Woodle ES**, Ghobreal I, Thistlethwaite JR, Bluestone JA. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. *Transplantation* 50: 608, 1990.
22. **Woodle ES**, Budzinski J, Pitman M, Flanagan L, Boone P, Smith C, Whittington PF, Emond JC, Broelsch CE. Reduced size liver transplantation in children. *AORN* 52: 252-260, 1990.
23. **Woodle ES**, Thistlethwaite JR, Emond JC, Broelsch CE: Successful hepatic transplantation in congenital absence of recipient portal vein. *Surgery* 107: 475-479, 1990.
24. Emond JC, Whittington, PF, Thistlethwaite JR, Cherqui D, Alonso EA, **Woodle ES**, Vogelbach P, Busse-Henry SM, Zucker AR, Broelsch CE: Transplantation of two patients with one liver: Analysis of a preliminary experience with "split liver" grafting. *Annals of Surgery* 212: 14-22, 1990.
25. Ellenhorn JDI, **Woodle ES**, Thistlethwaite JR, Bluestone JA. T lymphocyte activation following OKT3 treatment. *Current Surgery* 47: 458-461, 1990.

26. **Woodle ES**, Thistlethwaite JR, Stuart FP, Jolliffe LK, Fucello AJ, Bluestone JA. T-cell activation and lymphokine production induced by anti-human CD3 monoclonal antibodies. *Transplantation Proceedings* 23: 81-83, 1991.
27. **Woodle ES**, Thistlethwaite JR, Emond JC, Whittington PF, Black DD, Aran PP, Baker AL, Stuart FP, Broelsch CE. OKT3 therapy for hepatic allograft rejection: differential response in adults and children. *Transplantation* 51: 1207-1212, 1991.
28. **Woodle ES**, Thistlethwaite JR, Ghobrial I, Jolliffe LK, Stuart FP, Bluestone JA. OKT3 F(ab')₂ fragments: Retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. *Transplantation* 52: 354-360, 1991.
29. **Woodle ES**, Thistlethwaite JR, Jolliffe LK, Fucello AJ, Stuart FP, Bluestone JA. Anti-CD3 monoclonal antibody therapy: An approach toward optimization by in vitro analysis of new anti-CD3 antibodies. *Transplantation* 52: 361-368, 1991.
30. **Woodle ES**, Perdrizet G, Brunt EM, So SKS, Jendrisak MD, McCullough CS, Vehe KL, White HM, Peters MG, Marsh JW. FK-506: Reversal of humorally-mediated rejection following ABO-incompatible liver transplantation. *Transplantation Proceedings* 23: 2992-2993, 1991.
31. **Woodle ES**, Thistlethwaite JR, Jolliffe LK, Zivin RA, Collins A, Adair JR, Bodmer M, Athwal D, Alegre ML, Stuart FP, Bluestone JA. Humanized OKT3 antibodies: Successful transfer of immune modulating properties and idiotype expression. *Journal of Immunology* 148: 2756-2763, 1992.
32. **Woodle ES**, Perdrizet G, Brunt EM, So SKS, Jendrisak MD, McCullough CS, Vehe KL, White HM, Peters MG, Marsh JW. FK 506: Inhibition of humoral mechanisms of hepatic allograft rejection. *Transplantation* 54: 377-381, 1992.
33. Phelan DL, Thompson C, Henschell J, Miller L, **Woodle ES**, Pasque M. Heart transplantation across preformed class I antibody using FK 506. *Human Immunology* 34: 70, 1992.
34. Piper JB, Whittington PF, **Woodle ES**, Newell KA, Alonso EM, Emond JC, Heffron TG, Broelsch CE, Thistlethwaite JR. Pediatric liver transplantation at the University of Chicago Hospitals. *Clinical Transplantation* 9: 179-89, 1992.
35. **Woodle ES**, Darcy M, White H, Picus D, Hicks M, So S, Jendrisak M, McCullough C, Peters M, Marsh JW. Intrahepatic portosystemic vascular stents: A bridge to hepatic transplantation. *Surgery* 113: 344-351, 1993.
36. **Woodle ES**, Marsh JW, Perdrizet GA, So SKS, Jendrisak MD, White HM, Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. *Transplantation Proceedings* 25: 1988-1989, 1993.
37. Frank BD, **Woodle ES**, Perdrizet GA, White HM, Marsh JW, Lemann W. The neurotoxicity of FK 506 in liver transplant recipients. *Transplantation Proceedings* 25: 1877-1888, 1993.

38. **Woodle ES**, Marsh JW, Perdrizet GA, So SKS, Jendrisak MD, White HM. FK 506 rescue therapy: The rapidity of rejection reversal is related to the subsequent development of CMV disease. *Transplantation Proceedings* 25: 1992-1993, 1993.
39. **Woodle ES**, Marsh JW, Perdrizet GA, So SKS, Jendrisak MD, White HM. FK 506 rescue therapy: Early conversion improves efficacy. *Transplantation Proceedings* 25: 1990-1991, 1993.
40. US Multicenter FK 506 Liver Study Group: Klintmalm GB, Gonwa T, Wiesner RH, Krom RAF, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, Busuttil RW, McDiarmid S, Esquivel CO, Nakazato P, Marsh JW, **Woodle ES**, Kalayoglu M, D'Alessandro AM, Pirsch JD, Miller C, Schwartz M, Lewis WD, Monaco AP, Jenkins RL, Emond JC, Thistlethwaite JR, Whittington PF, Steinmuller DR, Fitzsimmons WE, Lawrence I. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. *Transplantation Proceedings* 25: 635-637, 1993.
41. US Multicenter FK 506 Liver Study Group: Klintmalm GB, Gonwa T, Wiesner RH, Krom RAF, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, Busuttil RW, McDiarmid S, Esquivel CO, Nakazato P, Marsh JW, **Woodle ES**, Kalayoglu M, D'Alessandro AM, Pirsch JD, Miller C, Schwartz M, Lewis WD, Monaco AP, Jenkins RL, Emond JC, Thistlethwaite JR, Whittington PF, Steinmuller DR, Fitzsimmons WE, Lawrence I. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. *Transplantation Proceedings* 25: 641-643, 1993.
42. US Multicenter FK 506 Liver Study Group: Klintmalm GB, Gonwa T, Wiesner RH, Krom RAF, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, Busuttil RW, McDiarmid S, Esquivel CO, Nakazato P, Marsh JW, **Woodle ES**, Kalayoglu M, D'Alessandro AM, Pirsch JD, Miller C, Schwartz M, Lewis WD, Monaco AP, Jenkins RL, Emond JC, Thistlethwaite JR, Whittington PF, Steinmuller DR, Fitzsimmons WE, Lawrence I. Use of FK 506 as rescue therapy for refractory rejection after liver transplantation. *Transplantation Proceedings* 25: 679-688, 1993.
43. So S, Mayo C, McCullough C, Jendrisak M, **Woodle ES**, Wallis M, Bailey T. Cytomegalovirus prophylaxis in pediatric renal transplant recipients. *Transplantation Proceedings* 25: 1414-1415, 1993.
44. **Woodle ES**, Phelan DL, Saffitz JE, Mohanakumar R, Shenoy S, Pasque M. FK 506: Reversal of humorally-mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. *Transplantation* 56: 1271-1275, 1993.
45. Shiroki R, Poindexter NJ, **Woodle ES**, Hussain MS, Mohanakumar T, Sharp DW. Human peripheral blood lymphocyte reconstituted severe combined immunodeficient (hu-PBL-SCID) mice: A model for human islet allograft rejection. *Transplantation* 57: 1555-1562, 1994.

46. Piper JB, Whittington PF, **Woodle ES**, Newell KA, Alonso EM, Thistlethwaite JR. Living related liver transplantation in children: A report of the first 58 recipients at the University of Chicago. *Transplant International*, Suppl 1: S111-S113, 1994.
47. Smith DM, Bluestone JA, Jeyarajah DR, Engelhard VH, Thistlethwaite JR, **Woodle ES**. Inhibition of T cell activation by a monoclonal antibody reactive against the $\alpha 3$ domain of human MHC class I molecules. *Journal of Immunology* 153: 1054-67, 1994.
48. **Woodle ES**, Perdrizet GA, So SKS, White HM, Marsh JW. FK506 rescue therapy for hepatic allograft rejection: Experience with an aggressive approach. *Clinical Transplantation* 9: 45-52, 1995.
49. Smith DM, Bluestone JA, Thistlethwaite JR, **Woodle ES**. Inhibition of T-cell activation by an anti-human Class I MHC reactive monoclonal antibody occurs at a point distal to TCR-CD3 mediated signal transduction. *Transplantation Proceedings* 27: 395-397, 1995.
50. Jeyarajah DR, Kadakia RA, O'Toole K, Newell KA, Josephson MA, Spargo BH, **Woodle ES**, Thistlethwaite JR. Changes in urinary cytokine mRNA profile after successful therapy for acute cellular renal allograft rejection. *Transplantation Proceedings* 27: 887-899, 1995.
51. Newell KA, **Woodle ES**, Millis JM, Piper JB, Huss E, Seaman DS, Bruce DS, Thistlethwaite JR. Pancreas transplantation with portal venous drainage and enteric exocrine drainage offers early advantages without compromising safety or allograft function. *Transplantation Proceedings* 27: 3002-3003, 1995.
52. Bruce DS, Newell KA, **Woodle ES**, Millis JM, Piper JB, Seaman DS, Huss E, and Thistlethwaite JR. Late complications in kidney-pancreas transplant recipients. *Transplantation Proceedings* 27: 3118, 1995.
53. The Mycophenolate Mofetil Renal Refractory Rejection Study Group: Conti D, Baker J, Wynn J, Deierhoi M, Stuart F, **Woodle E**, Ferguson R, Gonwa T, Pescovitz M, Stiller C, Mendez R, Rosenthal J, Pirsch J, Cohen D, Cerilli J, Barker C, Kauffman R, Linna J, Monroe S, Navarro M, Dunn J, Inokuchi S, Tomlanovich S, Wilburn R, Light J. Rescue therapy with mycophenolate mofetil. *Clinical Transplantation* 10: 131-135, 1996.
54. The Mycophenolate Mofetil Renal Refractory Rejection Study Group: Conti D, Baker J, Wynn J, Deierhoi M, Stuart F, **Woodle E**, Ferguson R, Gonwa T, Pescovitz M, Stiller C, Mendez R, Rosenthal J, Pirsch J, Cohen D, Cerilli J, Barker C, Kauffman R, Linna J, Monroe S, Navarro M, Dunn J, Inokuchi S, Tomlanovich S, Wilburn R, Light J. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. *Transplantation* 61: 722-729, 1996.
55. **Woodle ES**, Hussain S, Bluestone JA. In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8⁺ T cells. *Transplantation* 61: 798-803, 1996.

56. Millis JM, Bruce DS, Newell KA, Piper JB, **Woodle ES**, Seaman DS, Baker AL, Hart J, Dasgupta K, Thistlethwaite JR. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. *Transplantation Proceedings* 28: 1014, 1996.
57. **Woodle ES**, Haas M, Josephson MA, Newell KA, Bruce DS, Millis JM, Piper JB, charette jl, and Thistlethwaite JR. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. *Transplantation Proceedings* 28: 998-999, 1996.
58. Millis JM, **Woodle ES**, Piper JB, Bruce DS, Newell KA, Seaman DS, Baker AL, Hart J, Dasgupta K, Thistlethwaite JR. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. *Transplantation* 61: 1365-1369, 1996.
59. **Woodle ES**, Spargo B, Ruebe M, charette j. Treatment of acute glomerular rejection with FK 506. *Clinical Transplantation* 10: 266-270, 1996.
60. Newell KA, Alonso EM, Whittington PF, Bruce DS, Millis JM, Piper JB, **Woodle ES**, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR. Posttransplant lymphoproliferative disease in pediatric liver transplantation: Interplay between primary Epstein-barr virus infection and immunosuppression. *Transplantation* 62: 370-375, 1996.
61. Bruce DS, Newell KA, **Woodle ES**, Millis JM, Piper JB, Huss E, Thistlethwaite JR. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation. *Transplantation Proceedings* 28: 2136-2137, 1996.
62. Bruce DS, Newell KA, Josephson MA, **Woodle ES**, Piper JB, Millis JM, Seaman DS, Carnrike CLM, Huss E, Thistlethwaite JR. Long-term outcome of kidney-pancreas transplant recipients with good graft function at one year. *Transplantation* 62: 451-456, 1996.
63. **Woodle ES**, Thistlethwaite JR, Gordon JH, for the Tacrolimus Kidney Transplant Rescue Study Group. A multicenter trial of FK 506 (tacrolimus) therapy in refractory acute renal allograft rejection. *Transplantation* 62: 594-599, 1996.
64. **Woodle ES**, Bruce DS, Josephson M, Newell KA, Piper JB, Millis JM, Cronin D, Whitman G, Ruebe M, Thistlethwaite JR. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation. *Clinical Transplantation* 10: 323-333, 1996.
65. **Woodle ES**, Bruce DS, Josephson MA, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection. *Clinical Transplantation* 10: 389-395, 1996.
66. Millis JM, Seaman DS, Piper JB, Alonso EM, Kelly S, Hackworth CA, Newell KA, Bruce DS, **Woodle ES**, Thistlethwaite JR, Whittington PF. Portal vein thrombosis and stenosis in pediatric liver transplantation. *Transplantation* 62: 748-754, 1996.

67. **Woodle ES**, Cronin D, Newell KA, Millis JM, Bruce DS, Piper JB, Haas M, Josephson MA, Thistlethwaite JR. Tacrolimus therapy for refractory renal allograft rejection: Definition of the histologic response by protocol biopsies. *Transplantation* 62: 906-910, 1996.
68. Seaman DS, Newell KA, Piper JB, Bruce DS, **Woodle ES**, Cronin DC, Alonso EM, Whittington PF, Thistlethwaite JR, Millis JM. Use of a polytetrafluoroethylene patch for temporary wound closure after pediatric liver transplantation. *Transplantation* 62: 1034-1036, 1996.
69. Newell KA, Bruce DS, Piper JB, Millis JM, **Woodle ES**, Huss E, Cronin DC, Thistlethwaite JR. Comparison of pancreas transplantation with portal venous and enteric exocrine drainage to the standard technique utilizing bladder drainage of exocrine secretions. *Transplantation* 62: 1353-1356, 1996.
70. The Mycophenolate Mofetil Renal Refractory Rejection Study Group: Conti D, Baker J, Wynn J, Deierhoi M, Stuart F, **Woodle E**, Ferguson R, Gonwa T, Pescovitz M, Stiller C, Mendez R, Rosenthal J, Pirsch J, Cohen D, Cerilli J, Barker C, Kauffman R, Linna J, Monroe S, Navarro M, Dunn J, Inokuchi S, Tomlanovich S, Wilburn R, Light J. Rescue therapy with mycophenolate mofetil. *Transplantation Proceedings* 28: 34-36, Supp 1, 1996.
71. **Woodle ES**, Thistlethwaite JR, Gordon JH for the Tacrolimus Kidney Transplantation Rescue Study Group. Tacrolimus therapy for refractory acute renal allograft rejection: A prospective multicenter trial. *Transplantation Proceedings* 28: 3163-3164, 1996.
72. **Woodle ES**, Smith DM, Bluestone JA, Kirkman III WM, Green DR, and Skowronski EW. Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway. *Journal of Immunology* 158: 2156-2164, 1997.
73. Tesi RJ, Kano JH, Horn HR, Schroeder TJ, Gaber AO, First MR, Gaston RS, Mendez R, Mulloy LL, Light JA, Gaber LW, Squiers E, Taylor RJ, Neylan JF, Steiner RW, Knechtle S, Norman DJ, Shihab F, Basadonna G, Brennan DC, Hodge EE, Kahan BD, Kahana L, Steinberg S, **Woodle ES**, Chan L, Ham JM, Stratta RJ, Wahlstrom E, Lamborn KR, Moran HB, Pouletty P. Thymoglobulin reverses acute renal allograft rejection better than ATGAM: A double blinded randomized clinical trial. *Transplantation Proceedings* 29: 215-235, 1997.
74. Cronin DC, Bruce DS, Newell KA, Josephson MA, Millis JM, Piper JB, Ruebe M, Kirby M, Thistlethwaite JR, **Woodle ES**. Tacrolimus therapy for refractory renal allograft rejection: Experience with steroid withdrawal. *Transplantation Proceedings* 29: 307, 1997.
75. Cronin DC, Alonso EM, Piper JB, Newell KA, Bruce DS, **Woodle ES**, Whittington PF, Thistlethwaite JR, Millis JM. Biliary complications in living donor liver transplantation. *Transplantation Proceedings* 29: 419-420, 1997.

76. Newell KA, Alonso EM, Millis JM, Piper JB, Bruce DS, **Woodle ES**, Cronin DC, Whittington PF, Thistlethwaite JR. Retransplantation for failed hepatic allografts in children. *Transplantation Proceedings* 29: 442-443, 1997.
77. Millis JM, Cronin DC, Piper JB, Newell KA, Bruce DS, **Woodle ES**, Davis B, Seaman E, Thistlethwaite JR. Impact of a liberalized donor acceptance policy on liver transplantation. *Transplantation Proceedings* 29: 484, 1997.
78. **Woodle ES**, Smith DM, Bluestone JA, Green DR, Skowronski EW. Class I MHC mediates programmed cell death in a Fas-independent manner. *Transplantation Proceedings* 29: 1101, 1997.
79. Millis JM, Cronin DC, Newell KA, Piper JB, **Woodle ES**, Bruce DS, Conjeevarum H, Baker AL, Thistlethwaite JR. Tacrolimus treatment of steroid resistant rejection provides economic advantages compared with OKT3 therapy. *Transplantation Proceedings* 29: 1549, 1997.
80. Ross LF, Rubin DT, Siegler M, Josephson MA, Thistlethwaite JR, **Woodle ES**. Ethics of a paired kidney exchange program. *New England Journal of Medicine* 336: 1752-1755, 1997.
81. **Woodle ES**, Smith DM, Zhou N. Class I MHC mediates programmed cell death in human lymphoid cells. *Transplantation* 64: 140-146, 1997.
82. **Woodle ES**, Newell KA, Haas M, Bartosh S, Josephson MA, Millis JM, Bruce DS, Piper JB, Aronson AJ, Thistlethwaite JR. Reversal of accelerated renal allograft rejection with FK 506. *Clinical Transplantation* 11: 251-254, 1997
83. Bruce DS, Newell KA, **Woodle ES**, Cronin DC, Grewal HP, Millis JM, Ruebe M, Josephson MA, Thistlethwaite JR. Synchronous pancreas-kidney transplantation with portal venous and enteric exocrine drainage: Outcome in 70 consecutive cases. *Transplantation Proceedings* 30: 270-271, 1998.
84. Bruce DS, **Woodle ES**, Newell KA, Millis JM, Cronin DC, Loss GE, Pellar S, Josephson MA, Thistlethwaite JR. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. *Transplantation Proceedings* 30: 507-508, 1998.
85. Gaber LW, Moore LW, Gaber AO, First MR, Guttman RD, Pouletty P, Schroeder TJ, Soullillou JP, Alsina J, Cantarovich D, Chapman J, Charpentier B, Cohen D, First MR, Glotz D, Halloran P, Hunsicker L, Koene R, Legendre C, Leichtman A, Margreiter R, Matas A, Ponticelli C, Remuzzi G, **Woodle ES**, for the 1995 Efficacy Endpoints Conference. Utility of standardized histological classification in the management of acute rejection. *Transplantation* 65: 376-380, 1998.
86. Newell KA, Millis JM, Arnow PM, Cronin DC, Bruce DS, **Woodle ES**, Loss GE, Grewal HP, Siegel CT, Lissoos T, Schiano T, Mead J, Thistlethwaite JR. Incidence and outcome of infection by vancomycin-resistant enterococcus following orthotopic liver transplantation. *Transplantation* 65: 439-442, 1998.

87. Newell KA, Millis JM, Bruce DS, **Woodle ES**, Cronin DC, Loss G, Grewal H, Alonso EM, Dillon JJ, Whittington PF, Thistlethwaite JR. An analysis of hepatic retransplantation in children. *Transplantation* 65: 1172-1178, 1998.
88. Chiu MY, Sprague SM, Bruce DS, **Woodle ES**, Thistlethwaite JR, Josephson MA. Analysis of fracture prevalence in kidney-pancreas allograft recipients. *Journal of American Society of Nephrology* 677-683, 1998.
89. **Woodle ES**, Kulkarni S, Zhou N. Anti-human class I a3 domain-specific monoclonal antibody induces programmed cell death in murine cells expressing human class I MHC transgenes. *Transplantation Proceedings* 30: 1059-1060, 1998.
90. Kulkarni S, Holman P, Kranz D, Zhou N, Van Seventer J, **Woodle ES**. Construction of a single-chain antibody derived from 5H7, a monoclonal antibody specific for a death signaling domain of human class I major histocompatibility complex. *Transplantation Proceedings* 30: 1081, 1998.
91. Turner C, Bruce DS, Cronin DC, Loss GE, Grewal H, Siegel C, Millis JM, Newell KA, Davis B, Todo Y, Thistlethwaite JR, **Woodle ES**. Tacrolimus therapy for refractory acute renal allograft rejection: A four year experience with an aggressive approach. *Transplantation Proceedings* 30: 1234-1235, 1998.
92. Loss GE, Grewal H, Siegel C, Peace D, Mead J, Bruce DS, Cronin DC, Millis JM, Newell KA, **Woodle ES**. Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. *Transplantation Proceedings* 30: 1249-1250, 1998.
93. **Woodle ES**, Jordan ML, Facklam D, and Danovitch GA for the Refractory Rejection Metaanalysis Study Group. Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. *Transplantation Proceedings* 30: 1297-1298, 1998.
94. **Woodle ES**, Bluestone JA, Zivin RA, Jolliffe LK, Auger J, Dick R, Xu D, Thistlethwaite JR. Humanized, nonmitogenic OKT3 antibody, huOKT3[?]1(Ala-Ala): Initial clinical experience. *Transplantation Proceedings* 30: 1369-1370, 1998.
95. Grewal HP, Thistlethwaite JR, Loss GE, Bruce DS, Siegel CT, Cronin DC, Newell KA, Millis JM, **Woodle ES**. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil-based immunosuppression. *Transplantation Proceedings* 30: 1378-1379, 1998.
96. Millis JM, Cronin DC, Newell KA, Bruce DS, **Woodle ES**, Grewal HP, Loss GE, Lissoos T, Conjeevaram H, Schiano T, O'Laughlin R, charette j, McNaughton M, Baker AL, Thistlethwaite JR. Successful use of tacrolimus for initial rejection episodes after liver transplantation. *Transplantation Proceedings* 30: 1407-1408, 1998.
97. Loss GE, Brady L, Grewal HP, Siegel CT, Mead J, Bruce DS, Cronin DC, **Woodle ES**, Newell KA, Thistlethwaite JR, Millis JM. Cyclosporine versus cyclosporine

- microemulsion in pediatric liver transplant recipients. *Transplantation Proceedings* 30: 1435-1436, 1998.
98. Bruce DS, **Woodle ES**, Newell KA, Millis JM, Cronin DC, Loss GE, Grewal HP, Siegel CT, Pellar S, Josephson MA, Thistlethwaite JR. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. *Transplantation Proceedings* 30: 1538-1540, 1998.
 99. Delmonico FL, Stoff JS, Milford E, Harmon WE, **Woodle ES**. Living unrelated organ donation: An exchange proposal. *Graft* 1: 119-121, 1998.
 100. Gaber AO, First MR, Tesi RJ, Gaston RS, Mendez R, Mulloy LL, Light JA, Gaber LW, Squiers E, Taylor RJ, Neylan JF, Steiner RW, Knechtle S, Norman DJ, Shihab F, Basadonna G, Brennan DC, Hodge EE, Kahan BD, Kahana L, Steinberg S, **Woodle ES**, Chan L, Ham JM, Stratta RJ, Wahlstrom E, Lamborn KR, Horn HR, Moran HB, Pouletty P, Schroeder TJ. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. *Transplantation* 66: 29-37, 1998.
 101. Dachman AH, Newmark GM, Mitchell MT, **Woodle ES**. Helical CT examination of potential kidney donors. *American Journal of Roentgenology* 171: 193-200, 1998.
 102. Grewal HP, Thistlethwaite JR, Loss GE, Fisher JS, Cronin DC, Siegel CT, Newell KA, Bruce DS, **Woodle ES**, Brady L, Kelly S, Boone P, Oswald K, Millis JM. Complications in 100 living-liver donors. *Annals of Surgery* 228: 214-219, 1998.
 103. **Woodle ES**, Millis JM, So SKS, McDiarmid SV, Busuttill RW, Esquivel CO, Whittington PF, Thistlethwaite JR. Liver transplantation in the first three months of life. *Transplantation* 66: 606-609, 1998.
 104. **Woodle ES**, Kulkarni S. Programmed cell death. *Transplantation* 66: 681-691, 1998.
 105. **Woodle ES**, First MR, Gaber AO, Gaston RS, Mendez R, Mulloy LL, Kano JM, Schroeder TJ, for the US Multicenter Thymoglobulin Study Group. Twelve month outcome of the double blind, randomized, multicenter rejection trial of thymoglobulin vs atgam in renal transplants. *Graft* 2S: 24-27, 1999.
 106. **Woodle ES**. Corticosteroid withdrawal in renal transplantation. *Transplantation Proceedings* 31: 247-248, 1999.
 107. Miller J, Deierhoi MB, Filo RS, Jensik SC, Klassen D, Laskow D, Marsh C, Mendez R, Norman DJ, Pirsch J, Pruett T, Vincenti F, **Woodle ES**, Keilani T, Ayers M. Tacrolimus and mycophenolate mofetil in renal transplant recipients: One year results of a multicenter, randomized dose ranging trial. *Transplantation Proceedings* 31: 276-277, 1999.
 108. Haas M, Meehan SM, Josephson MA, Wit EJC, **Woodle ES**, Thistlethwaite JR. Smooth muscle-specific actin levels in the urine of renal transplant recipients:

Correlation with cyclosporine or tacrolimus nephrotoxicity. *American Journal of Kidney Diseases* 34: 69-84, 1999.

109. **Woodle ES**, Xu D, Zivin RA, Auger J, charette j, O'Laughlin R, Peace D, Jolliffe LK, Bluestone JA, Thistlethwaite JR. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3 γ_1 (Ala-Ala) in the treatment of acute renal allograft rejection. *Transplantation* 68: 608-616, 1999.
110. Millis JM, Bruce DS, Newell KA, Piper JB, Seaman DS, Rajasekar M, **Woodle ES**, Alonso EM, Whittington PF, Thistlethwaite JR. Hepatic allograft rescue with urgent reoperation after early vascular thrombosis in pediatric recipients. *Journal of Liver Transplantation and Surgery* (in press)
111. Millis JM, Seaman DS, Bruce DS, Newell KA, Piper JB, **Woodle ES**, Rajasekar M, Alonso EM, Whittington PF, Thistlethwaite JR. Living related liver transplantation and portal vein conduits: The search for patency. *Journal of Liver Transplantation and Surgery* (in press)
112. Millis JM, **Woodle ES**, Cronin DC, Newell KA, Piper JB, Bruce DS, Conjeevaram H, Baker AL, Hart J, Dasgupta K, Thistlethwaite JR. Tacrolimus is superior to OKT3 for the treatment of steroid resistant rejection in liver transplant patients. *Transplantation* (in press)
113. **Woodle ES**, Kulkarni S, Zhou N. A murine transgenic model of human class I MHC-mediated programmed cell death. *Transplantation Proceedings* (in press)
114. Mendez R, Deierhoi M, Filo RS, Jensik SR, Klassen D, Laskow D, Marsh C, Miller J, Norman D, Pirsch JD, Pruett TL, Ulanki F, **Woodle ES**. Tacrolimus and mycophenolate mofetil in renal transplant recipients: Six month results of a multicenter, randomized dose ranging study. *Transplantation Proceedings* (in press)
115. **Woodle ES**, Buell J, Siegel C, Kulkarni S, Kopelan A, Grewal HP. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: The Chicago experience. *Transplantation Proceedings* 31: 84S-85S, 1999.
116. Gaber LW, Moore LW, Gaber AO, Tesi RJ, First MR, Meyer J, Schroeder TJ for the US Multicenter Thymoglobulin Study Group. Correlation of histology to clinical rejection reversal: A thymoglobulin multicenter trial report. *Kidney International* 55: 2415-2422, 1999.
117. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wienser RH, Swinnen LJ, **Woodle ES**, Bromberg JS for the ASTS/ASTP EBV-PTLD task force and the Mayo Clinic organized international consensus development meeting on EBV-induced post-transplant lymphoproliferative disorders (PTLD). EBV-induced post-transplant lymphoproliferative disorders (PTLD). *Transplantation* 68: 1517-1525, 1999.
118. Josephson MA, Chiu M, **Woodle ES**, Thistlethwaite JR,. Drug-induced acute interstitial nephritis in renal allografts: Histiopathologic features and clinical course in six patients. *American Journal of Kidney Disease* 34: 540-548, 1999.

119. Meehan SM, Siegel CT, Aronson AJ, Bartosh SM, Thistlethwaite JR, **Woodle ES**, Haas M. The relationship of untreated borderline infiltrates by the Banff criteria to acute rejection in renal allograft biopsies. *J Am Soc Nephrol* 10: 1806-1814, 1999.
120. Ross LF, **Woodle ES**. Ethical issues in increasing living kidney donations by expanding kidney paired exchange programs. *Transplantation* 69: 1539-1543, 2000.
121. Pirsch J, Bekersky I, Vincenti F, Boswell G, **Woodle ES**, Alak A, Kruelle M, Fass N, Mekki Q, Facklam D. Co-administration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: Pharmacokinetics and tolerability. *Journal of Clinical Pharmacology* 40: 527-532, 2000.
122. Chen LM, Godinez J, Thisted RA, **Woodle ES**, Thistlethwaite JR, Powers C, Haraf D. New scoring system identifies patients who benefit from radiation therapy in refractory acute renal allograft rejection. *International Journal Radiation Oncology* 46: 999-1003, 2000
123. Kulkarni S, Holman PO, Kopelan A, van Seventer GA, van Seventer JM, Kranz DM, **Woodle ES**. Programmed cell death signaling via cell surface expression of a single death antibody transgene. *Transplantation* 69: 1209-1217, 2000.
124. Millis JM, Cronin DC, Brady LM, Newell KA, **Woodle ES**, Bruce DS, Thistlethwaite JR, Broelsch CE. Primary living-donor liver transplantation at the University of Chicago: Technical aspects of the first 104 recipients. *Annals of Surgery* 232:104-111, 2000
125. Miller J, Mendoz R, Pirsch JD, Jensik SC for the FK506/MMF Dose-Ranging Kidney Transplant Study Group: Deierhoi MB, Filo RS, Jensik SC, Klassen D, Laskow DA, Marsh C, Miller J, Norman DJ, Pirsch JD, Pruett T, Vincenti F, **Woodle ES**, Keilani T, Erdman J, Huang C, Ayers M, and Facklam DP. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. *Transplantation* 69: 875-880, 2000.
126. Grewal H, Brady L, Cronin DC, Loss GE, Siegel CT, Oswald K, Fisher JS, Bruce DS, **Woodle ES**, Aronson AJ, Thistlethwaite JR, Millis JM, Newell KA. Combined liver and kidney transplantation in children. *Transplantation* 70: 100-105, 2000
127. Kahan BD, Steinberg S, Bartlett S, Mendez R, Weinstein S, Lorber M, Gaber AO, Butt K, Dunn J, Leichtman A, Taylor R, Danovitch G, Gores P, Pescovitz M, Tomlanovich S, Scandling J, Wright F, Neylan J, **Woodle ES**, Bertolatus A, Velosa J, Conti D, Brayman K, Fisher R, Wombolt D, Adams P, Inokuchi S, VanBuren D, Fairchild R, Matas A, Badosa F, Monaco A, Pollack R, Meyers S, Ettenger R, Laskow D, Strom T, Miller J. Sirolimus (Rapamune, Rapamycin) is more effective than azathioprine to reduce the incidence of acute renal allograft rejection episodes when used in combination with cyclosporine and prednisone: a phase III U.S. multicenter trial. *Lancet* 356: 1768-1769, 2000.

128. Buell JF, Bruce DS, Alverdy J, Newell KA, Yoshida A, Limsrichamrern S, **Woodle ES**. Hand-assisted laparoscopic living donor nephrectomy. *J Am Coll Surg* 192: 132-136, 2001
129. Zenios SA, **Woodle ES**, Friedman Ross L. Primum non nocere: Avoiding increased waiting times for individual racial and blood-type subsets of kidney wait list candidates in a living donor/cadaveric donor exchange program. *Transplantation* 74: 648-654, 2001.
130. Buell JF, Edye M, Li C, Johnson M, Koffron A, Kuo PC, Hanaway M, Johnson LB, Leventhal J, Newell KA, Bruce DS, Jacobs S, **Woodle ES**, Cho E, Bartlett ST, Flowers JL. Are concerns over right laparoscopic donor nephrectomy unwarranted? *Annals of Surgery* 233: 645-651, 2001.
131. Buell JF, Thistlethwaite JR, Yoshida A, Kristo B, Kim E, Siegal C, Newell KA, Schmidt M, Cronin DC, Millis JM, **Woodle ES**, Bruce DS. Renal failure in african-americans with diabetes: Should they be treated with combined kidney-pancreas transplantation. *Transplantation* 2001(in press).
132. Buell JF, Yoshida A, Kristo B, Kim E, Newell KA, Cronin DC, **Woodle ES**, Bruce DS Thistlethwaite JR, Millis JM. Liver Transplantation for hepatocellular cancer: A selective approach based on pre-operative diagnosis. submitted *Transplantation* 2001 (in press).
133. Whiting JF, Martin JE, Cohen D, Woodward R, Singer G, Lowell J, Howard T, **Woodle ES**, Brennan D, Schnitzler MA. Economic outcome of simultaneous pancreas kidney transplantation compared with kidney transplantation alone. *Transplantation Proceedings*. 33: 1923, 2001.
134. First MR, Peddi VR, Weiskittel P, Woodle ES. Control of risk factors for cardiovascular disease in long-term renal transplant recipients. *Transplantation Proceedings*. 33, 3674-3675, 2001.
135. Buell JF, Trofe J, Hanaway MJ, Rosengard B, Rilo HR, Alloway RR, Beebe T, First MR, **Woodle ES**. Transmission of donor cancer into cardiothoracic transplant recipients. *Surgery* 130 (4): 660-668, 2001.
136. **Woodle ES**, Buell JF, Hanaway MJ, First MR, Trofe J. Biologic behavior of carcinoid tumors in solid organ transplant recipients: The Israel Penn International Transplant Tumor Registry. *Transplantation Proceedings* 33, 3656-3657, 2001.
137. **Woode ES**, Hanaway MJ, Buell JF, Gross T, First, Trofe, Beebe T. Kaposi's sarcoma: Analysis of the U.S. and International experiences from the Israel Penn International Transplant Tumor Registry. *Transplantation Proceedings* 33, 3660-3661 2001.
138. Peddi VR, Weiskittel P, Alexander JW, **Woodle ES**, First MR. HLA-Identical renal transplant recipients: Immunosuppression, long-term complications and survival. *Transplantation Proceedings* 33, 3411-3413, 2001.

139. Trofe J, Buell JF, First MR, Hanaway MJ, Beebe TM, **Woodle ES**. The role of immunosuppression in lymphoma. (in press)
140. Paduval RD, Meehan SM, **Woodle ES**, Thistlethwaite RJ, Haas M, Cronin DC, Vats A, Josephson MA. Successful retransplantation following renal allograft loss to polyoma virus interstitial nephritis. Transplantation (in press).
141. Alexander JW, Stanley LL, Ofstedal TL, First MR, Cardi MA, Safdar S, Mendoza NC, Munda R, Fidler JP, Buell JF, Hanaway MJ, **Woodle ES**. Transplantation without steroids. Transplantation Proceedings. (in press).
142. Trofe J, Cavallo T, First MR, Alloway RR, Roy-Chaudhury P, Weiskittel P, Peddi VR, **Woodle ES**. Polyomavirus in kidney and kidney pancreas transplantation. Transplantation Proceedings. (in press).
143. Buell J, Hanaway M, Trofe J, Gross T, Beebe T, First MR, **Woodle ES**. Gastric cancer in transplant recipients: Does aggressive monitoring impact morbidity? Transplantation Proceedings. (in press).
144. Buell J, Hanaway M, Trofe J, Gross T, Beebe T, First MR, **Woodle ES**. Sarcomas: A rare lesion in transplant recipients? Transplantation Proceedings. (in press).
145. Buell J, Hanaway M, Trofe J, Gross T, Beebe T, First MR, **Woodle ES**. Immunosuppression and Merkel cell cancer. Transplantation Proceedings. (in press).
146. Buell J, Hanaway M, Trofe J, Hanaway M, First MR, **Woodle ES**. De novo breast cancer in kidney transplant recipients. Transplantation Proceedings. (in press).
147. **Woodle ES**. Corticosteroid elimination in renal transplantation: pro. Transplantation Proceedings. (in press).
148. Gaithe L, Arriola M, Pattin M, Sabatiello R, Schiavelli R, Casaliva A, Nagy P, Boccardo G, Sedevich A, Incardona C, **Woodle ES**. Prospective multicenter trial of early steroid withdrawal with tacrolimus/mycophenolate therapy in renal transplant recipients. Transplantation Proceedings (in press).
149. Hanaway M, Buell JF, Munda R, **Woodle ES**. Laparoscopic living donor kidney transplantation technical modifications of recipient and donor operations address problem with short renal vessels and obviate the need for interposition vascular grafts. Transplantation (in press).
150. Buell JF, Hanaway MJ, **Woodle ES**. Maximizing renal artery length in right laparoscopic donor nephrectomy by retrocaval exposure of the aortorenal junction. Transplantation (in press).

SUBMITTED ARTICLES

1. Millis JM, Cronin DC, Newell KA, **Woodle ES**, Bruce DS, Loss GE, Grewal HP, Conjeevaram H, Baker AL, Dasgupta K, Thistlethwaite JR. The economic impact of tacrolimus and OKT3 in the treatment of steroid resistant rejection in liver transplant patients. *Transplantation*
2. **Woodle ES**, Cronin D, Loss GE, Bruce DS, Josephson MA, Newell KA, Millis JM, Grewal HP, Ruebe M, Kirby M, Thistlethwaite JR. A prospective trial of corticosteroid withdrawal following tacrolimus therapy for refractory renal allograft rejection. *Clinical Transplantation*
3. Meehan SM, Siegel CT, **Woodle ES**, Aronson AJ, Bartosh SM, Thistlethwaite JR, Haas M. Clinicopathologic course of untreated borderline infiltrates by the Banff criteria in renal allograft biopsies. *Kidney International*
4. Fisher JS, Siegel CT, Mead J, **Woodle ES**. A guide to using tacrolimus in the treatment of refractory renal transplant rejection. *Biodrugs*
5. Kulkarni S, Loss G, Siegel C, Buell J, Yoshida A, Kopelan A, Todo T, **Woodle ES**. Tacrolimus-based regimens provide effective therapy for antibody-mediated acute renal allograft rejection. *Transplantation*
6. Fisher JS, **Woodle ES**, Thistlethwaite JR. Kidney transplantation procedures: Monitoring and immunosuppression. *World Journal of Surgery*
7. Kulkarni S, Zhou N, Kopelan A, **Woodle ES**. A murine model for human class I MHC-mediated programmed cell death. *Transplantation*
8. Buell JF, Hanaway MD, Potter SR, Koffron A, Kuo PC, Leventhal J, Munda R, Cho E, Johnson M, Edey M, **Woodle ES**. Surgical techniques in right laparoscopic donor nephrectomy. *Journal American College of Surgeons*
9. Aull MJ, Buell JF, Peddi VR, Trofe J, Beebe TM, Hanaway MJ, Roy-Chaudhury P, Alloway RR, First MR, **Woodle ES**. Maltoma: A helicobacter pylori-associated malignancy in transplant recipients. *Transplantation*

ARTICLES IN PREPARATION

1. Millis JM, Bruce DS, Newell KA, Piper JB, **Woodle ES**, Seaman DS, Baker AL, Hart J, Dasgupta K, Thistlethwaite JR. The use of tacrolimus for initial treatment of steroid resistant rejection in liver transplant recipients. (for Transplantation)
2. Bruce DS, **Woodle ES**, Newell KA, Cronin DC, Millis JM, Ruebe M, Josephson MA, Thistlethwaite JR. Mycophenolate mofetil and microemulsified cyclosporine in kidney-pancreas transplantation. (for Clinical Transplantation)
3. Filo RS, Laskow D, Miller J, Pirsch J, Shapiro R, Vincenti F, **Woodle ES**. Suggested guidelines for the use of tacrolimus in kidney-transplant recipients.
4. Turner C, Bruce DS, Cronin DC, Grewal H, Loss GE, Siegel C, Millis JM, Newell KA, Davis B, Todo Y, Thistlethwaite JR, **Woodle ES**. Tacrolimus therapy for refractory acute renal allograft rejection: A four year experience with an aggressive approach. (for Transplantation)
5. Grewal HP, Thistlethwaite JR, Loss GE, Cronin DC, Siegel CT, Newell KA, Bruce DS, Millis JM, **Woodle ES**. Corticosteroid cessation 1 week following renal transplantation using tacrolimus (TAC) / mycophenolate mofetil (MMF)-based immunosuppression. (for Transplantation)
6. **Woodle ES**, Wynne J, Lamborn K, Pouletty P, Canafax DM, Irish WD. Multivariate logistic regression analysis of the U.S. multicenter, double-blinded, randomized thymoglobulin versus Atgam trial for the treatment of acute renal allograft rejection. (for Transplantation)
7. Buell JF, Thistlethwaite R, Kristo B, Yoshida A, Siegel CT, Schmidt MJ, Kim E, Newell KA, Cronin DC, Millis JM, **Woodle ES**, Bruce DS. Impact of racial differences in simultaneous kidney-pancreas transplantation in diabetic renal failure. (For Transplantation)
8. Alexander JW, Ofstedal T, Stanley L, Erickson A, Greenberg N, First MR, James L, Whiting JF, **Woodle ES**. Dietary supplementation with L-arginine and canola oil reduces rejection episodes, renal biopsies, rehospitalization and blood pressure following renal transplantation.
9. Buell JF, Trofe J, Rosengard B, Hanaway MJ, Rilo H, Beebe T, First MR, **Woodle ES**. Transmission of Donor Cancer into Cardio-Thoracic Transplant Recipients. (for Surgery).
10. Aull MJ, Buell JF, Hanaway MJ, Cardi M, Peddi VR, Weiskittel P, Berilla E, Meredith L, Trofe J, Zavala E, Alloway RR, Roy-Chaudhury, First MR, **Woodle ES**. Long-term outcomes in renal transplantation using non-heart-beating donors and donor characteristics that may predict successful utilization of these organs.
11. Aull MJ, Buell JF, Hanaway MJ, Cardi M, Peddi VR, Weiskittel P, Berilla E, Meredith L, Trofe J, Zavala E, Alloway RR, Roy-Chaudhury, First MR, **Woodle ES**. Maltoma:

In solid organ transplant recipients: A report from the Israel Penn International Transplant Tumor Registry.

12. Buell JF, Hanaway MJ, Woodle ES. Maximizing renal artery length in right laparoscopic donor nephrectomy by retrocaval exposure of the aorta renal junction.

PUBLISHED ABSTRACTS AND LETTERS

1. **Woodle ES**, DR Vera, RE Ward, DP Hutak, RC Stadalnik: Tc99m-Galactosyl-neoglycoalbumin (Tc-NGA) liver imaging: Potential application in liver transplantation. *Journal of Nuclear Medicine* 25: 66-67, 1983.
2. Vera DR, **Woodle ES**, Krohn KA, Schiebe PO, Stadalnik RC: Validation of a kinetic model for receptor-mediated uptake of Tc99m-Galactosyl-neoglycoalbumin (Tc-NGA). *Journal of Nuclear Medicine* 25:63, 1983.
3. Stadalnik RC, Vera DR, **Woodle ES**, Hutak D, Ward RE, Krohn KA: Use of Tc99m-Galactosyl-neoglycoalbumin (Tc-NGA) to determine hepatic blood flow. *Journal of Nuclear Medicine* 25:66, 1983.
4. **Woodle ES**, Nichols BG, Ward RE, Bogusky RT: ³¹P NMR in the *in vitro* porcine liver. Society of Magnetic Resonance in Medicine, 2nd Annual Meeting, New York, New York, 1983.
5. **Woodle ES**, Ward RE, Vera DR, Stadalnik RC: Tc99m-Galactosyl-neoglycoalbumin (Tc-NGA) liver imaging: A means for patient selection in liver transplantation. *Clinical Nuclear Medicine* 9:42, 1983.
6. Stadalnik RC, Vera DR, Krohn KA, **Woodle ES**, Schiebe PO: Clinical potential of technetium-labelled receptor ligands. Society of Nuclear Medicine Symposium on Receptor-based Radiopharmaceuticals, Las Vegas, 1983.
7. **Woodle ES**, Ward RE, Vera DR, Stadalnik RC: Technetium-99m-Galactosyl-neoglycoalbumin (Tc-NGA) liver imaging: Application in liver transplantation. *Journal of Nuclear Medicine* 26:9, 1984.
8. Vogelbach P, Emond J, Thistlethwaite JR, **Woodle ES**, Henry SB, Broelsch CE: Preservation of the liver with University of Wisconsin solution: Initial experience at the University of Chicago. *Z Gastroenterology* 68:27, 1989.
9. **Woodle ES**, Thistlethwaite JR, Stuart FP, Jolliffe LK, Fucello AJ, Bluestone JA. Anti-human CD3 monoclonal antibodies: activation and lymphokine production are dependent on antibody isotype and epitope specificity. *Fed Proceedings* 4: 2795, 1990.
10. Collins A, Pulito V, Garrison L, Olsen W, Ghobrial I, McMahon M, Schnell J, Rao P, Adair J, Bebbington C, **Woodle ES**, Bluestone J, Jolliffe L, Zivin R. Construction, expression, and functional analysis of a chimeric anti-CD4 (chimeric OKT4A) antibody. *Fed Proceedings* 4: 2270, 1990.
11. Smith DM, Jeyarajah DR, Hussain MS, **Woodle ES**, Thistlethwaite, JR, Bluestone JA. Human T-lymphocyte activation in response to anti-CD3 monoclonal antibody, alloantigen or xenoantigen is inhibited by a monoclonal anti-HLA class I reactive antibody. *Journal of Immunology* 150:269A, 1993.

12. Smith DM, Bluestone JA, Kirkman WM, **Woodle ES**. Induction of apoptosis in normal and transformed human lymphocytes by a monoclonal antibody reactive against the $\alpha 3$ domain of class I MHC molecules. *Immunologist* (in press)
13. **Woodle ES**, Thistlethwaite JR, Gordon JH. A multicenter trial of FK 506 (Tacrolimus) rescue therapy in renal transplantation. *Journal of American Society of Nephrology* 6 (3): 1122, 1995.
14. Millis JM, Bruce DS, Newell KA, Piper JB, **Woodle ES**, Seaman, DS, Rajasekar M, Dasgupta K, Baker AL, Thistlethwaite JR. FK 506 is as effective as OKT3 for initial treatment for steroid resistant rejection in liver transplant patients. *Hepatology* 22: 143A, 1995.
15. **Woodle ES**, Millis JM, So SKS, McDiarmid SV, Piper JB, Whittington PF, Busuttill, Esquivel CO, Thistlethwaite JR. Liver transplantation in the first three months of life. *Pediatric Nephrology* 10: C56, 1996.
16. Millis JM, Piper JB, Alonso EM, Cronin DC, Newell KA, Bruce DS, **Woodle ES**, McNaughton M, Thistlethwaite JR, Whittington PF. 100 living donor liver transplants: Influence of recipient size on outcome. *Hepatology* 24: 180A, 1996.
17. Grewal HP, Thistlethwaite JR, Fisher J, Loss GE, Cronin DC, Newell KA, Bruce DS, **Woodle ES**, Millis JM. Is there late morbidity in living liver donors? A 5 year follow up. *Liver Transplant Surgery* 3: C-38, 1997.
18. Loss GE, Thistlethwaite JR, Hackworth CA, Newell KA, Grewal HP, Cronin DC, Bruce DS, **Woodle ES**, Millis JM. The effect of TIPS placement on pediatric orthotopic liver transplantation. *Liver Transplant Surgery* 3: C-86, 1997.
19. Millis JM, Hackworth C, Cronin DC, Grewal HP, Loss GE, Newell KA, Bruce DS, **Woodle ES**, Szymiski G, Lissoos T, Thistlethwaite JR. Safe outpatient removal of T tubes following liver transplantation. *Liver Transplant Surgery* 3: C-83, 1997.
20. Loss GE, Thistlethwaite JR, Grewal HP, Bruce DS, Cronin DC, Whittington PF, Newell KA, Kelly S, Alonso E, Oswald K, **Woodle ES**, Millis JM. Comparison of tacrolimus and OKT3 treatment of steroid-resistant acute hepatic allograft rejection in children. *Hepatology* 126: 234A, 1997.
21. Ross LF, **Woodle ES**, Siegler M. Authors' reply to Paired-Kidney-Exchange Programs. *New England Journal of Medicine* 19: 1392-1393, 1997.
22. Kulkarni S, Van Seventer J, Zhou N, Holman P, Kranz D, **Woodle ES**. Expression of a GPI-anchored, single-chain antibody specific for a cell death signaling domain of human class I MHC. *Transplantation* 65: S46, 1998.

23. Meehan SM, Siegel CT, Aronson AJ, Bartosh SM, Thistlethwaite JR, **Woodle ES**, Haas M. Clinicopathologic features of untreated borderline changes by the Banff criteria in renal allograft biopsies. *Transplantation* 65: S59, 1998.
24. Turner CD, Bruce DS, Cronin DC, Grewal H, Siegel C, Millis JM, Newell KA, Davis B, Todo T, Thistlethwaite JR, **Woodle ES**. Tacrolimus therapy for refractory acute renal allograft rejection: Differential responses in African-Americans and Caucasians. *Transplantation* 65: S61, 1998.
25. **Woodle ES**, Jordan ML, Shapiro R, Facklam D, Danovitch GA, Tomlanovich SJ, Deierhoi MH. Meta-analysis of tacrolimus and mycophenolate refractory rejection trials in renal transplantation. *Transplantation* 65: S64, 1998.
26. Turner CD, Bruce DS, Cronin DC, Grewal H, Loss GE, Siegel C, Millis JM, Newell KA, Davis B, Todo T, Thistlethwaite JR, **Woodle ES**. Tacrolimus therapy for refractory acute renal allograft rejection: A four year experience with an aggressive approach. *Transplantation* 65: S64, 1998.
27. Cronin DC, Brady L, Loss GE, Grewal HP, Siegel CT, **Woodle ES**, Bruce DS, Newell KA, Kelly S, Thistlethwaite JR, Millis JM. Transplantation of pediatric patients with fulminant hepatic failure: Improved survival with utilization of segmental allografts from live donors. *Transplantation* 65: S89, 1998.
28. **Woodle ES**, Kulkarni S, Zhou N. A murine transgenic model of human class I MHC-mediated programmed cell death. *Transplantation* 65: S96, 1998.
29. Grewal HP, Thistlethwaite JR, Loss GE, Cronin DC, Siegel CT, Newell KA, Bruce DS, Millis JM, **Woodle ES**. Early corticosteroid withdrawal 1 week following renal transplantation using tacrolimus (TAC) / mycophenolate mofetil (MMF)-based immunosuppression. *Transplantation* 65: S167, 1998.
30. **Woodle ES**, Ross LF. Paired exchanges should be part of the solution to ABO incompatibility in living donor kidney transplantation. *Transplantation* 66: 406-407, 1998.
31. **Woodle ES**, Canafax DM, Irish WD. Thymoglobulin (Thymo) may be more efficacious than Atgam for reducing recurrent acute renal allograft rejection: Results of the U.S. multicenter, double-blinded, comparative trial. *Journal of American Society of Nephrology* 9: 703A, 1998.
32. Grewal HP, Thistlethwaite JR, Loss GE, Cronin DC, Siegel CT, Newell KA, Bruce DS, Millis JM, **Woodle ES**. Early corticosteroid withdrawal one week following renal transplantation using tacrolimus (TAC)- / mycophenolate mofetil (MMF)-based immunosuppression. *American Society of Transplant Physicians, 17th Annual Meeting, Program and Abstracts book*, p. 243, 1998.
33. **Woodle ES**, Moore LW for the thymoglobulin Multicenter Study Group. Twelve month intent to treat analysis of the double blind, randomized multicenter

- thymoglobulin vs. atgam trial for the treatment of acute rejection following renal transplantation. *Transplantation* 66: S2, 1998.
34. Miller J, Deierhoi MB, Filo RS, Jensik SC, Klassen D, Laskow D, Marsh C, Mendez R, Norman DJ, Pirsch J, Pruett T, Vincenti F, **Woodle ES**, Keilani T, Ayers M. Tacrolimus and mycophenolate mofetil in renal transplant recipients: Six and twelve month results of a multicenter, randomized dose ranging study. *Transplantation* 66: S2, 1998.
 35. Grewal HP, Brady L, Cronin D, Loss GE, Siegel CT, Oswald K, Fisher JS, Bruce DS, **Woodle ES**, Millis JM, Thistlethwaite JR, Newell KA. Combined liver and kidney transplantation (LTK) in children. *Transplantation* 66: S50, 1998.
 36. Millis JM, Cronin DC, Newell KA, Bruce DS, **Woodle ES**, Siegel C, Brady L, Thistlethwaite JR. Elimination of hepatic artery thrombosis in living donor liver transplantation with microvascular reconstruction. *Hepatology* 28: 264A, 1998.
 37. **Woodle ES**. U.S. randomized comparative trial of tacrolimus-and cyclosporine-based regimens with concomitant MMF therapy. *New Horizons in Kidney Transplantation*, Lisbon, Portugal, March 8-9, 1999.
 38. **Woodle ES**. Corticosteroid withdrawal under long-term tacrolimus therapy. *New Horizons in Kidney Transplantation*, Lisbon, Portugal, March 8-9, 1999.
 39. Buell JF, Mead J, Yoshida A, Kulkarni S, Kristo B, Kim E, Siegel C, Fisher JS, Turner C, Bruce DS, Cronin DC, Millis JM, Thistlethwaite JR, Bruce DS, **Woodle ES**. African-American compared to caucasian response to corticosteroid withdrawal following tacrolimus therapy for refractory renal rejection. *Transplantation* 67: S163, 1999.
 40. Yoshida A, Brady L, Cronin D, Kelly S, Siegel C, **Woodle ES**, Millis JM. Steroid withdrawal in pediatric liver transplant recipients. *Transplantation* 67: S180, 1999.
 41. Kulkarni S, Holman P, Kranz D, van Seventer GA, Van Seventer J, Kopelan A, **Woodle ES**. Cell-mediated delivery of programmed cell death signals following gene transfer of a membrane-anchored single-chain antibody specific for class I MHC. *Transplantation* 67: S212, 1999.
 42. Siegel T, Mead J, Buell J, Yoshida A, Newell K, **Woodle ES**, Thistlethwaite JR, Bruce DS. Comparison of daclizumab vs. atgam induction in kidney pancreas transplantation. *Transplantation* 67: S223, 1999.
 43. Kopelan A, Kulkarni S, van Seventer JM, van Seventer GA, Zhou N, Todo T, **Woodle ES**. Class I MHC and FAS antibodies induce programmed cell death via pathways similar with respect to early but not late signaling events. *Transplantation* 67: S229, 1999.

44. Buell JF, Kristo B, Kopelan A, Kulkarni S, Yoshida A, Kim E, Siegel C, Cronin DC, Bruce DS, Newell KA, Millis JM, Thistlethwaite JR, **Woodle ES**. Early corticosteroid withdrawal with tacrolimus and mycophenolate mofetil (MMF) immunosuppression in renal transplantation: Eighteen month follow-up. *Transplantation* 67: S545, 1999.
45. Buell JF, Thistlethwaite JR, Kristo B, Yoshida A, Siegel C, Kim E, Newell K, Cronin D, Millis JM, **Woodle ES**. African-American patients with renal failure secondary to diabetes should be referred for combined kidney-pancreas transplant. *Transplantation* 67: S567, 1999.
46. Pescovitz MD, for the Rapamune US Study Group. Surgery, Indian University Medical Center, Indianapolis, IN. One-year safety and efficacy of sirolimus after renal transplant. *Transplantation* 69: S112, 2000.
47. Buell JF, Kulkarni S, Grewal HP, Kopelan A, Yoshida A, Swanson A, Cronin DC, Bruce DS, Newell KA, Thistlewaite JR, **Woodle ES**. Early corticosteroid cessation at one week following kidney transplant under tacrolimus and mycophenolate mofetil (MMF) immunosuppression, three year follow-up. *Transplantation* 69: S134, 2000.
48. Bryant M, Roy-Chaudhury P, **Woodle ES**, First MR. Thymoglobulin induction therapy in cadaveric renal allograft recipients: Intermittent dosing with CD3+lymphocyte count monitoring. *Transplantation* 69: S160, 2000.
49. Whiting JF, Martin J, Cohen D, Woodward R, Singer G, Lowell J, Howard T, **Woodle ES**, Brennen D, Schnitzler M. Economic outcomes of simultaneous kidney-pancreas transplantation (SKP) compared to kidney alone (KA). *Transplantation* 69: S270, 2000.
50. Alexander JW, Ofstedal T, Stanley L, Erickson A, Greenberg N, James L, First MR, Whiting JF, **Woodle ES**, Dietary supplements with l-arginine and canola oil reduces rejection episodes, renal biopsies rehospitalization and blood pressure following renal transplantation. *Transplantation* 69: S362.
51. Buell JF, Alverdy J, Newell KA, Yoshida A, Limsrichamrern S, Woodle ES, Bruce, DS. Hand-assisted laparoscopic live-donor nephrectomy. *American College of Surgeons* 192; 1: 132-136.
52. Buell JF, Bruce DS, Hanaway M, Yoshida A, Cronin DC, Munda R, Newell KA, **Woodle ES**. The hand-assisted modifications of the traditional laparoscopic donor nephrectomy retains its advantages over open donor nephrectomy while addressing shortcomings. *American Journal of Transplantation* 2001; 1(1): 471.
53. Hanaway MJ, Trofe J, Buell JF, Lo A, Alloway RR, Beebe T, **Woodle ES**. Colon cancer risk in liver transplant recipients: The Israel Penn International Transplant Tumor Registry Experience. *American Journal of Transplantation* 2001;1(1):264.

54. Hanaway MJ, Buell JF, Trofe J, Beebe T, **Woodle ES**. De novo liver cancer after liver transplantation. *American Journal of Transplantation* 2001; 1(1): 316.
55. Hanaway MJ, Buell JF, Lo A, Trofe J, Beebe T, First MR, **Woodle ES**. Kaposi's sarcoma in solid organ transplantation: Israel Penn International Transplant Tumor Registry Experience in the United States. *American Journal of Transplantation* 2001; 1(1): 327.
56. Buell JF, Trofe J, Hanaway MJ, First MR, Beebe T, Peddi VR, Rilo H, **Woodle ES**. Can patients with CNS tumors safely be used in expanding the donor pool? *American Journal of Transplantation* 2001; 1(1): 220.
57. Buell JF, Trofe J, Rosengard B, Hanaway MJ, Rilo H, Beebe T, First MR, **Woodle ES**. Transmission of donor cancer into cardio-thoracic transplant recipients. *American Journal of Transplantation* 2001; 1(1): 282.
58. Buell JF, Koffron A, Edye M, Johnson M, Arenas J, Kuo PC, Johnson LB, Bruce DS, Leventhal J, Cho E, Bartlett ST, Hanaway M, **Woodle ES**. 106 cases of right laparoscopic donor nephrectomy: A multicenter experience. *American Journal of Transplantation* 2001; 1(1): 471.
59. Buell JF, Johnson M, Koffron A, Fanelli F, Jacobs S, Bruce DS, Yoshida A, Newell KA, Arenas J, **Woodle ES**, Leventhal J, Cho E, Edye M, Kuo PC. 1200 laparoscopic living donor nephrectomies: Analysis of graft loss in the first year post transplant. *American Journal of Transplantation* 2001; 1(1): 304.
60. Buell JF, Koffron A, Hanaway M, Yoshida A, Bruce DS, Kuo PC, Leventhal J, Arenas J, Edye M, **Woodle ES**, Bartlett ST, Cho E, Johnson M. Influence of learning curve, surgeon type, and training type on the results of laparoscopic donor nephrectomy at nine transplant centers. *American Journal of Transplantation* 2001; 1(1): 304.
70. Buell JF, Aull M, Lo A, Hanaway MJ, Munda R, Alexander WJ, Fidler J, Rilo H, Hanto DH, Lo A, Hanaway M, Lewis D, First MR, **Woodle ES**. A donor selection algorithm for non-heart-beating donors allows high retrieval rates and excellent graft function. *American Journal of Transplantation* 2001; 1(1): 305.
71. Trofe J, Buell JF, Hanaway M, Beebe T, First MR, Alloway RR, Lo A, Rilo H, **Woodle ES**. Post-transplant lymphoproliferative disorder in kidney Transplantation: A 32-year experience in 405 patients from the Israel Penn Transplant Tumor Registry. *American Journal of Transplantation* 2001; 1(1): 376.
72. Trofe J, Buell JF, Hanaway M, First R, Beebe T, **Woodle ES**. Melanoma in solid organ transplantation: A 25 year experience in 143 patients from the Israel Penn International Transplant Tumor Registry. *American Journal of Transplantation* 2001; 1(1): 389.

73. Aull M, First MR, Cardi M, Peddi VR, Weiskittel P, Berilla E, Meredith L, J Trofe, Zavala E, Alloway RR, **Woodle ES**, Buell JF. Long-term graft function in renal transplantation using non-heart-beating donors. *American Journal of Transplantation* 2001; 1(1): 379.
74. Aull M, Trofe J, Alloway RR, Hanaway M, First MR, Wagoner L, Bebe T, **Woodle ES**, Buell JF. Experience with 274 cardiac transplant recipients post-transplant lymphoproliferative disorder: A report from the Israel Penn Transplant Tumor Registry. *American Journal of Transplantation* 2001; 1(1): 282.
75. Aull M, Alloway RR, Trofe J, First MR, Peddi VR, **Woodle ES**, Buell JF. Transmission of donor cancer during renal transplantation, report from the Israel Penn International Transplant Tumor Registry. *American Journal of Transplantation* 2001; 1(1): 472.
76. Peddi VR, Bryant M, Roy-Chaudhury, **Woodle ES**, First MR. Cost- Analysis of Thymoglobulin Induction with intermittent dosing based on CD3+ lymphocyte counts in high risk cadaver renal transplant recipients. . *American Journal of Transplantation* 2001; 1(1): 272.
77. Govil A, Peddi VR, Goel S, **Woodle ES**, First MR. Sirolimus substitution for calcineurin-inhibitors in renal allograft recipients with calcineurin-inhibitor nephrotoxicity. *American Journal of Transplantation* 2001; 1(1): 247.
78. Buell JF, Jeevanandrum, Cronin C. Yoshida A., Newell KA, Baker A, Josephson M, **Woodle ES**, Thistlethwaite JR, Anderson A, Millis JM. Has tacrolimus made multi-organ cardiac transplantation feasible or does the heart exert a protective effect over visceral transplants? *American Journal of Transplantation* 2001; 1(1): 324.
79. Peddi VR, Bryant M, Roy-Chaudhury P, **Woodle ES**, safety and efficacy of thymoglobulin induction with intermittent dosing based on CD3+lymphocyte counts in high-risk cadaver renal transplant recipients. *American Journal of Transplantation* 2001; 1(1): 406.
80. Aull M, Kelly B, Buell JF, Hanaway MJ, Weber F, Johnson S, Rolfes K, Zavala E, **Woodle ES**, Hanto DH. Morbid obesity: A contraindication to liver transplantation? *Liver Transplantation* 2001; 7(6):C-10.
81. Hanaway MJ, Trofe J, Buell JF, Lo A, Alloway RR, Beebe T, **Woodle ES**. The risk of colon cancer in liver transplant recipients. *Liver Transplantation*, 2001; 7(6):C-41.
82. Hanaway MJ, Buell JF, Trofe J, Beebe T, **Woodle ES**. De novo liver malignancy after liver transplantation. *Liver Transplantation* 2001; 7(6): C-39.
83. Hanaway MJ, **Woodle ES**, Trofe J, Beebe T, First MR, Buell JF. De novo lung cancer after liver transplantation. *Liver Transplantation* 2001; 7(6) C-40.

84. Buell JF, Trofe J, Hanaway MJ, Beebe T, Rilo HL, Peddi VR, Aull MJ, First MR, **Woodle ES**. Malignancies of the skin after liver transplantation: A report from the Israel Penn International Transplant Tumor Registry. *Liver Transplantation* 2001; 7(6): C-40.
85. Buell JF, Hanaway MJ, Trofe J, Lo A, Beebe T, Aranda-Michel J, Rilo HL, First MR, **Woodle ES**. Post-transplant lymphoproliferative disorder in liver transplant recipients: A report from the Israel Penn International Transplant Tumor Registry. *Liver Transplantation* 2001; 7(6): C-71.
86. Peddi VR, Roy-Chaudhury P, **Woodle ES**, First MR. Efficacy of Thymoglobulin induction with intermittent dosing based on CD3+ Lymphocyte counts in pancreas transplant recipients. International Pancreas and Islet Transplant Association, Innsbruck, Austria, June 14, 2001.
87. Peddi VR, Roy Chaudhury P, Munda R, **Woodle ES**, First MR. Impact of antiviral prophylaxis on cytomegalovirus (CMV) infection in pancreas transplant recipients in the current immunosuppression. International Pancreas and Islet Transplant Association, Innsbruck, Austria, June 14, 2001.
88. Alexander JW, Metze TJ, Goodman HR, First MR, Cardi MA, Safdhar S, Mendoza NC, Munda R, Fidler JP, Alloway RR, Buell JF, Hanaway MJ, Greenburg NA, **Woodle ES**. Simultaneous Corticosteroid Avoidance and Minimization of Calcineurin Inhibitors. *American Journal of Transplantation* (in press).
89. Buell JF, Potter SR, Hanaway MJ, Alexander JW, Munda R, Fidler J, Peddi VR, Roy-Chaudhury P, Cardi M, First MR, **Woodle ES**. Implications of Obesity in Laparoscopic Nephrectomy Donors. *American Journal of Transplantation* (in press).
90. Hanaway MJ, Buell JF, Munda R, Potter SR, Fidler J, Alexander JW, **Woodle ES**. Technical Modifications of the Recipient Operation to Address Limitations of Both Right and Left Laparoscopic Donor Nephrectomy in Renal Transplantation. *American Journal of Transplantation* (in press).
91. Buell JF, Koffron A, Hanaway MJ, Potter SR, Leventhal J, **Woodle ES** Comparison of Hand-Assisted and Traditional Laparoscopic Live Donor Nephrectomy: A Superior Method or Surgeons Preference. *American Journal of Transplantation* (in press).
92. Lee LY, Martin JE, Hanaway MJ, Weiskittel P, Munda R, Alexander JW, Cardi M, Peddi RV, Zavala E, Berilla E, Clippard M, First MR, **Woodle ES**, Buell JF. :Laparoscopic Vs Open Donor Nephrectomy: A Quality of Life Study. *American Journal of Transplantation* (in press).
93. Trofe J, Cavallo T, First MR, Roy-Chaudhury P, Peddi R, Weiskittel P, Bryant M, Brown S, Khalili K, Gordon J, Alloway RR, Hanaway MJ, Buell JF, **Woodle ES**. Polyomavirus in Kidney and Kidney/Pancreas Transplantation: Minimizing Renal

- Allograft Injury/Loss by Defined Immunosuppression Reduction and Histologic Monitoring. *American Journal of Transplantation* (in press).
94. Peddi VR, Govil A, Weiskittel P, Alloway RR, Goel S, **Woodle ES**, First MR. Long-Term Follow-Up of Sirolimus Substitution for Calcineurin-Inhibitors in Kidney and Kidney/Pancreas Allograft Recipients with Nephrotoxicity. *American Journal of Transplantation* (in press).
 95. Peddi VR, Brown S, Hanaway MJ, Buell JF, Alloway RR, Munda R, **Woodle ES**, First MR. Efficacy and Cost-Analysis of Thymoglobulin (TMG) Induction With Intermittent Dosing Based on CD3+ Lymphocyte Counts in Pancreas Transplant Recipients. *American Journal of Transplantation* (in press).
 96. **Woodle ES**, Hanaway MJ, Buell JF, Brown S, Alloway RR, Peddi VR, D'Alessio D, Rilo HR. Hypoglycemia Unawareness and Diabetes-Related Morbidity in Islet Transplant Candidates. *American Journal of Transplantation* (in press).
 97. Hanaway MJ, Rilo H, Brown S, Peddi VR, Buell JF, Alloway RR, D'Alessio D, **Woodle ES**. Hypoglycemic Unawareness: Characterization of Severity in Islet Transplant Candidates. *American Journal of Transplantation* (in press).
 98. Hanaway MJ, Rilo H, Brown S, Peddi VR, Buell JF, Alloway RR, D'Alessio D, **Woodle ES**. Hypoglycemic Unawareness: Characterization of Severity in Islet Transplant Candidates. *American Journal of Transplantation* (in press).
 99. Liu H, Iwanaga Y, Steffen C, Upshaw L, Schleuter K, Hossain SA, Hanaway MJ, **Woodle ES**, Trapnell BC, Rilo HR. Akt Overexpressing Protects Canine Islet and HIT-T15 Cells From Nitric Oxide-Mediated Cell Injury. *American Journal of Transplantation* (in press).
 100. Trofe J, Sethuraman G, Buell JF, Hanaway MJ, Aull MJ, Alloway RR, Wagoner L, Beebe TM, Gross TG, First MR, **Woodle ES**. Multivariate Analysis of Risk Factors that Influence Survival in Cardiac Transplant Recipients with PTLD. *American Journal of Transplantation* (in press).
 101. Trofe J, Sethuraman G, Buell JF, Hanaway MJ, First MR, Alloway RR, Gross TG, Beebe TM, **Woodle ES**. Multivariate Analysis of Risk Factors That Influence Survival in Renal Transplant Recipients with PTLD. *American Journal of Transplantation* (in press).
 102. Trofe J, Buell JF, First MR, Beebe TM, Aull MJ, Gross TG, Hanaway MJ, Alloway RR, **Woodle ES**. Renal Allograft Involvement by Post Transplant Lymphoproliferative Disorder: Clinical Implications. *American Journal of Transplantation* (in press).
 103. **Woodle ES**, Trofe J, Buell JF, Aull MJ, Hanaway MJ, Gross T, First MR, Beebe T. PTLD Demonstrates Distinct Differences in Kidney and Heart Transplant

- Recipients: The IPITTR Experience. *American Journal of Transplantation* (in press).
104. **Woodle ES**, Buell JF, Hanaway MJ, Beebe T, Peddi VR, Alloway RR, First MR, Trofe J. Biologic Behavior of Carcinoid Tumors in Solid Organ Transplant Recipients: The Israel Penn International Transplant Tumor Registry Experience. *American Journal of Transplantation* (in press).
 105. Buell JF, Gross T, Hanaway MJ, Trofe J, Beebe T, First MR, Peddi VR, **Woodle ES**. Transplantation for End-Stage Renal Disease Resulting from Bilateral Nephrectomies for Renal Cell Cancer. *American Journal of Transplantation* (in press).
 106. Buell JF, Hanaway MJ, Trofe J, Alloway RR, Beebe T, Gross T, First MR, **Woodle ES**. De novo Sarcomas: In Solid Organ Transplant Recipients. *American Journal of Transplantation* (in press).
 107. Buell JF, Gross TG, Hanaway MJ, Trofe J, Beebe T, Peddi VR, Roy-Chaudhury P, First MR, **Woodle ES**. Post-Transplant Lymphoproliferative Disorder: The Significance of Central Nervous System Involvement. *American Journal of Transplantation* (in press).
 108. Aull MJ, Buell JF, Gross TG, Trofe J, Alloway RR, Beebe TM, Hanaway MJ, First MR, **Woodle ES**. Transplantation in Patients with Pre-existing Leukemias. *American Journal of Transplantation* (in press).
 109. Aull MJ, Buell JF, Gross T, Trofe J, Alloway RR, Beebe TM, Hanaway MJ, First MR, **Woodle ES**. De novo Leukemias in Solid Organ Transplant Recipients: A Report From The Israel Penn International Transplant Tumor Registry. *American Journal of Transplantation* (in press).
 110. Buell JF, Hanaway MJ, Trofe J, Alloway RR, Beebe T, Aranda-Michel J, Gross T, First MR, **Woodle ES**. Post-Transplant Lymphoproliferative Disorder in Liver Transplant Recipients: Comparison Between Children and Adults. *American Journal of Transplantation* (in press).
 111. Buell JF, Hanaway MJ, Trofe J, Beebe T, Gross T, First MR, **Woodle ES**. Merkel Cell Cancer in Solid Organ Transplant Recipients. *American Journal of Transplantation* (in press).
 112. Hanaway MJ, Buell JF, James L, Alloway RR, Gross T, Trofe J, Beebe T, First MR, **Woodle ES**. De novo Cancer After Pancreas Transplantation: The IPITTR Experience. *American Journal of Transplantation* (in press).
 113. Hanaway MJ, Buell JF, Koffron A, Kaufman D, Bruce D, Pelletier R, Henry M, Stratta R, Gaber AO, James L, Alloway RR, First MR, Peddi VR, **Woodle ES**.

- PTLD in Pancreas Transplantation: A Multicenter Analysis. *American Journal of Transplantation* (in press).
114. Trofe J, Buell JF, First MR, Beebe TM, Hanaway MJ, Alloway RR, **Woodle ES**, Gross TG. Recurrence of Lymphoma Following Organ Transplantation. *American Journal of Transplantation* (in press).
 115. Gross TG, Buell JF, Hanaway MJ, Beebe TM, Trofe J, Alloway RR, First MR, **Woodle ES**. Wilms' Tumor and Organ Transplantation. *American Journal of Transplantation* (in press).
 116. **Woodle ES**, Buell JF, Hanaway MJ, Trofe J, Aull MJ, Gross T, First MR, Alloway RR, Beebe T. Kaposi's Sarcoma: Differential Clinical Patterns in U.S. and International Patients. *American Journal of Transplantation* (in press).
 117. Worley K, Weber F, Hanaway MJ, Aranda-Michel J, Sherman K, Kelly B, Martin J, Auble P, Bass M, Zucker S, Zavala E, Hanto DW, **Woodle ES**, Buell JF. Successful Use of Short-Term Anti-HBs Therapy to Increase the Use of Hepatitis B Core Antibody Positive Liver Allografts. *American Journal of Transplantation* (in press).
 118. Gavigan KM, Martin JE, Large AR, Rolfes K, Auble P, Bass M, Trumbull L, Zavala EY, Weber F, Hanaway MJ, Hanto DW, **Woodle ES**, Buell JF, Aranda-Michel J. Aggressive Pre-Transplant Intervention Results in Decreased Bone Complications in Adult Liver Transplant Recipients. *American Journal of Transplantation* (in press).
 119. Zavala EY, Rilo HR, Hanaway MJ, Brown SF, Peddi VR, First MR, Martin JE, Alloway RR, Buell JF, Matthews JB, **Woodle ES**. An Economic Evaluation of Human Islet Transplantation. *American Journal of Transplantation* (in press).
 120. Zavala EY, Rilo HR, Hanaway MJ, Pandolfo A, Alloway RR, First MR, Peddi VR, Brown SF, Buell JF, Matthews JB, **Woodle ES**. Economics of Establishing an Islet Isolation Laboratory for Human Islet Transplantation. *American Journal of Transplantation* (in press).
 121. Zavala EY, Rogers JC, First MR, **Woodle ES**. Potential Negative Impact On Academic Kidney Transplant Programs by the Balanced Budget Act of 1997 that Extends ESRD Coordination of Benefits to 30 Months. *American Journal of Transplantation* (in press).

SUBMITTED ABSTRACTS

1. Millis JM, Cronin DC, Newell KA, Bruce DS, **Woodle ES**, Brady L, Thistlethwaite JR. Elimination of hepatic artery thrombosis in living donor liver transplantation with microvascular reconstruction. American Association for the Study of Liver Diseases International Association for the Study of the Liver, Chicago, Illinois, November 4-10, 1998. (submitted 6/98)
2. Buell JF, Alverdy J, Yoshida A, Siegel CT, **Woodle ES**. Hand-assisted modification of the laparoscopic living donor nephrectomy procedure: A user friendly approach. American Society of Transplant Surgeons, Chicago, Illinois, May 19-21, 1999. (submitted 1/99)
3. Kopelan A, Kulkarni S, van Seventer J, van Seventer G, Zhou N, Todo T, **Woodle ES**. Class I MHC antibodies induce programmed cell death via a pathway distinct from FAS. Sixth Basic Sciences Symposium of the Transplantation Society, Monterey Peninsula, California, August 25-29, 1999. (submitted 3/99)
4. Buell JF, Grewal HP, Kopelan A, Kulkarni S, Yoshida A, Swanson A, Siegel C, Cronin D, Bruce DS, Newell KA, Millis JM, Thistlethwaite JR, **Woodle ES**. Early corticosteroid withdrawal with tacrolimus and mycophenolate mofetil (MMF) immunosuppression in renal transplantation: Two-year follow-up. Minnesota Transplant Congress, Minneapolis, Minnesota, October 20-23, 1999. (submitted 6/99)
5. Gaite L, Arriola M, Pattin M, Sabatiello R, Schiavelli R, Casaliva A, Nagy P, Boccardo G, Sedevich A, Incardona, C, **Woodle ES**. Prospective multicenter trial of early steroid withdrawal with tacrolimus/mycophenolate therapy in renal transplant recipients. XVIII International Congress of the Transplantation Society, Rome, Italy, August 27 – September 1, 2000. (submitted 1/2000)
6. Peddi VR, Bryant M, Roy-Chaudhury P, **Woodle ES**, First MR. Thymoglobulin Induction therapy in cadaveric renal allograft recipients: Intermittent dosing with CD3+ lymphocyte count monitoring. XVIII International Congress of the Transplantation Society, Rome, Italy, August 27 – September 1, 2000. (submitted 1/2000)
7. Alexander JW, Ofstedal T, Stanley L, Ericson A, Greenberg N, First MR, Whiting JF, **Woodle ES**. L-Arginine and canola oil improve outcome after renal transplantation. XVIII International Congress of the Transplantation Society, Rome, Italy, August 27 – September 1, 2000. (submitted 1/2000)
8. Aull MJ, Peddi VR, Trofe J, First MR, Hanaway M, Beebe TM, Alloway RR, Buell JF, **Woodle ES**. Maltoma: Infectious etiology of malignancy in transplants patients. International Transplant Nurses Society, Cambridge England, August 29-September 1, 2001.

9. Beebe TM, Buell JF, Alloway RR, Hanaway MJ, Trofe J, First MR, **Woodle ES**. Donor transmission of a renal cell carcinoma from a living related donor to a kidney recipient. International Transplant Nurses Society, Cambridge, England, August 29-September 1, 2001.
10. Buell JF, Beebe TM, Lo A, Trofe J, Hanaway MJ, First MR, Woodle ES. De novo breast cancer in kidney transplant recipients. International Transplant Nurses Society, Cambridge, England, August 29-September 1, 2001.
11. Lumsden AB, Haag BW, Escobar FS, Hood DB, Cofer JB, **Woodle ES**. Prospective, randomized multicenter trial of stepped venaflo ePTFE grafts compared to IMPRA stepped ePTFE grafts in hemodialysis. *Vascular Access for Hemodialysis V*. (submitted 2/2000).
12. Nagy P, Casaliva A, Pattin M, Sabatiello R, Schiavelli R, Sedevich A, Boccardo G, Arriola M, Gaitte L, Coordinacion: Incardona C, **Woodle ES**. Estudio multicentrico prospective en transplantados renales tratados con Tacrolimus, micofenolato mofetil y retirada precoz de esteroides. Third Congress of the Transplantation Society of the Southern Cone/Third Congress of the Uruguayan Society of Transplantation, Punta Del Este, Uruguay, March 16, 2000.
13. Alexander JW, Stanley LL, Ofstedal TL, First MR, Cardi MA, Anderson PA, Mendoza NC, Munda R, Fidler JP, Buell JF, Hanaway MJ, **Woodle ES**. A Pilot Study of Corticosteroid Free and Low Calcineurin Inhibitor Immunosuppression Regimen For Renal Transplantation. (submitted Transplant Immunosuppression 2001).
14. Aull M, Buell JF, Peddi VR, Trofe J, First MR, Hanaway MJ, Beebe TM, Alloway RR, **Woodle ES**. Development of maltoma in multiorgan transplant patients. (submitted Transplant Immunosuppression 2001).
15. Buell JF, Hanaway M, Beebe TM, Lo A, Trofe J, Gross T, First MR, **Woodle ES**. Incidence and management of sarcomas in transplant recipients. (submitted Society of Surgical Oncology 2001).
16. Buell JF, Hanaway M, Beebe TM, Lo A, Trofe J, Gross T, First MR, **Woodle ES**. Merkel cell cancer in transplant recipients. (submitted Society of Surgical Oncology 2001).
17. Lo A, Buell JF, Thistlethwaite JR, Cronin DC, Newell KA, Bruce DS, Hanaway MJ, **Woodle ES**, Millis JM. Association between portal enteric drainage and acute rejection in simultaneous kidney pancreas transplant. (submitted International Transplantation 2001).
18. Lo A, Buell JF, Thistlethwaite JR, Cronin DC, Newell KA, Bruce DS, Hanaway MJ, **Woodle ES**, Millis JM. Clinical experience with 114 portal enteric drainage

- simultaneous kidney pancreas transplants. (submitted International Transplantation 2001).
19. Buell JF, Kulkarni S, Kopelan A, Yoshida A, Siegel CT, DasGupta K, Shortridge K, Baker A, Conjeevaram H, Newell KA, **Woodle ES**, Thistlethwaite JR, Millis JM, Bruce DS. A randomized trial of veno-venous bypass in Orthotopic liver transplantation. (submitted Transplantation 2001).
 20. Kelly B, Buell JF, Cronin DC, Hanaway MJ, Newell KA, Millis JM, **Woodle ES**, Bruce DS. Long and short term financial and programmatic impact of hand assisted laparoscopic donor nephrectomy. (submitted Surgery 2001).
 21. First MR, Peddi VR, Weiskittel P, **Woodle ES**. Control of risk factors for cardiovascular disease in long-term renal transplant recipient. 2001 A Transplant Odyssey, Istanbul, Turkey, August 20-24, 2001.
 22. Peddi VR, Weiskittel P, Alexander JW, **Woodle ES**, First MR. HLA-identical renal transplant recipients: Immunosuppression, Long-term complications, and survival. 2001 A Transplant Odyssey, Istanbul, Turkey, August 20-24, 2001.
 23. Roy-Chaudhury p, Miller MA, Reaves A, Peddi VR, **Woodle ES**, First MR, Smith R. Cytokine expression and cellular phenotyping in transplant glomerulopathy. ASN/ISN World Congress of Nephrology. San Francisco, California, October 2001.
 24. Govil A, Peddi VR, Goel S, Roy-Chaudhury, Weiskittel P, **Woodle ES**, First MR. Sirolimus substitution for calcineurin- inhibitors in renal allograft recipients with nephrotoxicity. ASN/ISN World Congress of Nephrology. San Francisco, California, October 2001.
 25. Levy SB, Martin JE, Weiskittel P, Peddi VR, Buell JF, **Woodle ES**, First MR. A 33-year experience with late corticosteroid withdrawal in 139 stable renal transplant recipients and impacts on associated cardiovascular risk factors. ASN/ISN World Congress of Nephrology. San Francisco, California, October 2001.
 26. Buell JF, Hanaway MJ, Trofe J, First MR, **Woodle ES**. Immunosuppression and merkel cell cancer. Society of Surgical Oncology, (submitted 8/31/01).
 27. Buell JF, Hanaway MJ, Trofe J, Beebe T, Gross T, First MR **Woodle ES**. Transplant related malignancies: The Israel Penn International Transplant Tumor Registry. Society of Surgical Oncology, (submitted 8/31/01).
 28. Buell JF, Hanaway MJ, Trofe J, Beebe T, First MR, **Woodle ES**. Gastric cancer in transplant recipients: Does aggressive monitoring impact morbidity. Central Surgical Association, (submitted 9/01/01).

POSTERS

1. **Woodle ES**, Jordan ML, Shapiro R, Facklam D, Danovitch GA, Tomlanovich SJ, Deierhoi MH. Meta-analysis of tacrolimus & MMF trials. American Society of Transplant Physicians, May, 1998.
2. Turner CD, Bruce DS, Cronin, Loss GE, Grewal H, Siegel C, Millis JM, Newell KA, Davis B, Todo T, Thistlethwaite JR, **Woodle ES**. Tacrolimus therapy for refractory acute renal allograft rejection: Differential responses in African-Americans and caucasians. XVII World Congress of the Transplantation Society, Montreal, Canada, July, 1998.
3. Kulkarni S, Van Seventer J, Zhou N, Holman P, Kranz D, **Woodle ES**. Expression of a GPI-anchored, single-chain antibody specific for a cell death signaling domain of human class I MHC. XVII World Congress of the Transplantation Society, Montreal, Canada, July, 1998.
4. **Woodle ES**, Jordan ML, Shapiro R, Facklam D, Danovitch GA, Tomlanovich SJ, Deierhoi MH. Meta-analysis of tacrolimus and mycophenolate refractory rejection trials in renal transplantation. XVII World Congress of the Transplantation Society, Montreal, Canada, July 13, 1998.
5. Bruce DS, **Woodle ES**, Newell KA, Siegel C, Buell J, Yoshida A, Thistlethwaite JR. A simplified arterial reconstruction for pancreas transplantation with portal venous drainage. 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, August 22, 1999.
6. Aull M, Trofe J, Alloway RR, Hanaway M, First MR, Wagoner L, Beebe T, **Woodle ES**, Buell JF. PTLD in cardiac transplantation: A report on 274 patients from the Israel Penn International Transplant Tumor Registry. Third International Symposium on Immunodeficiencies and malignancies. Berlin, Germany, February 17, 2001.
7. Buell JF, Trofe J, Hanaway MJ, First MR, Beebe T, Peddi VR, Rilo H, **Woodle ES**. Can patients with CNS tumors safely be used in expanding the donor pool? Transplant 2001, Chicago, May 13, 2001.
8. Hanaway MJ, Buell JF, Trofe J, Beebe T, **Woodle ES**. De novo liver cancer after liver transplantation. Transplant 2001, Chicago, May 14, 2001.
9. Hanaway MJ, Buell JF, Lo A, Trofe J, Beebe T, First MR, **Woodle ES**. Kaposi's sarcoma in solid organ transplantation: Israel Penn International Transplant Tumor Registry: Experience in the United States. Transplant 2001, Chicago, May 14, 2001.
10. Buell JF, Johnson M, Koffron A, Fanelli F, Jacobs S, Bruce DS, Yoshida A, Newell KA, Arenas J, **Woodle ES**, Leventhal J, Cho E, Edye M, Kuo PC. 1200

laparoscopic living donor nephrectomies: analysis of graft loss in the first year post transplant. Transplant 2001, Chicago, May 14, 2001.

11. Buell JF, Koffron A, Hanaway M, Yoshida A, Bruce DS, Kuo PC, Leventhal J, Arenas J, Edye M, **Woodle ES**, Bartlett ST, Cho E, Johnson M. Influence of learning curve, surgeon type, and training type on the results of laparoscopic donor nephrectomy at nine transplant centers. Transplant 2001, Chicago, May 14, 2001.
12. Buell JF, Aull M, Lo A, Hanaway MJ, Munda R, Alexander WJ, Fidler J, Rilo H, Hanto DH, Lo A, Hanaway M, Lewis D, First MR, **Woodle ES**. A donor selection algorithm for non-heart-beating donors allows high retrieval rates and excellent graft function. Transplant 2001, Chicago, May 14, 2001.
13. Buell JF, Jeevannandrum V, Cronin DC, Yoshida A, Newell KA, Baker A, Josephson M, **Woodle ES**, Thistlethwaite JR, Anderson A, Mills JM. Has tacrolimus made multi-organ cardiac transplantation feasible or does the heart exert a protective effect over visceral transplants? Transplant 2001, Chicago, May 14, 2001
14. Peddi VR, Bryant M, Roy-Chaudhury P, **Woodle ES**. Safety and efficacy of thymoglobulin Induction with intermittent dosing based on CD3+lymphocyte counts in high-risk cadaver renal transplant recipients. Transplant 2001, Chicago, May 15, 2001.
15. Peddi VR, Roy-Chaudhury P, Buell JF, **Woodle ES**, First MR. Cost Analysis of Induction with Intermittent dosing based on CD3+lymphocyte counts in pancreas transplant recipients. International Pancreas and Islet Transplant Association Innsbruck, Austria, June 14, 2001.
16. Trofe J, Cavallo T, Frist MR, Alloway RR, Roy-Chaudhury P, Weiskittel P, Peddi VR, **Woodle ES**. Polyomavirus in kidney and kidney pancreas transplantation. The 2nd International Congress on Immunosuppression, December 6-8, 2001.
17. Alexander JW, Stanley LL, Ofstedal TL, First MR, Cardi MA, Safdar S, Mendoza NC, Munda R, Fidler JP, Buell JF, Hanaway MJ, **Woodle ES**. Transplantation without steroids. The 2nd International Congress on Immunosuppression, December 6-8, 2001.

BOOK CHAPTERS

1. Piper JB, **Woodle ES**, Newell KA, Whittington PF, Alonso EM, Edmond JC, Heffron TG, Broelsch CE, Thistlethwaite JR. Pediatric Liver Transplantation at The University of Chicago Hospitals. In: Terasaki P, ed., Clinical Transplants 1992, p. 179-189, Los Angeles, UCLA Press.
2. **Woodle ES**. Multiple Organ Recovery: Liver. In: M. Wayne Flye, ed., Atlas of Organ Transplantation, 1995, p. 47-78, Philadelphia, Saunders.
3. Marsh JW, **Woodle ES**, Flye MW. Adult Liver Transplantation. In: M. Wayne Flye, ed., Atlas of Organ Transplantation, 1995, p. 147-180, Philadelphia, Saunders.
4. Anderson CB, Jendrisak MD, **Woodle ES**, Flye MW. Adult Renal Transplantation. In: M. Wayne Flye, ed., Atlas of Organ Transplantation, 1995, p. 101-122, Philadelphia, Saunders.
5. Flye MW, Anderson CB, **Woodle ES**, Jendrisak MD. Living Related Renal Transplantation. In: M. Wayne Flye, ed., Atlas of Organ Transplantation, 1995, p. 127-134, Philadelphia, Saunders.
6. **Woodle ES**, Knoerzer MP, Newell KA, Hackworth C, Rosenbloom J, Leef J. Stenotic Lesions Associated with AV Grafts for Hemodialysis: Experience with Intraoperative Balloon Angioplasty and Postoperative Endovascular Stent Placement. In: Vascular Access for Hemodialysis - IV, p. 169-174, W.L. Gore & Associates, Inc., 1995.
7. Millis JM, Alonso EM, Piper JB, Bruce DS, Newell KA, **Woodle ES**, Baker AL, Whittington PF, Thistlethwaite JR. Liver Transplantation at the University of Chicago. In: Cecka and Terasaki, eds., Clinical Transplants 1995, p. 187-197, Los Angeles, UCLA Press, 1995.
8. **Woodle ES**. Surgical Versus Radiologic Intervention for Arteriovenous Graft Thrombosis/Stenosis: The Case for Surgery. In: Vascular Access for Hemodialysis - V, p. 53-62, W.L. Gore & Associates, Inc., 1997.
9. Ross LF, **Woodle ES**. Kidney Exchange Programs: An Expanded View of the Ethical Issues. In: Touraine, Traeger, Betuel, Dubernard, Revillard, and Dupuy, eds., Organ Allocation, Citic 30, p.285-295, 1998.
10. Kulkarni S, Kopelan A, **Woodle ES**. Tacrolimus Therapy in Renal Transplantation. In: Morris PJ, ed., Kidney Transplantation, W.B. Saunders, Chapter 17, p.251-262, 2001.

SUBMITTED BOOK CHAPTERS

1. **Woodle ES**, Buell JF, First MR. The Israel Penn International Transplant Registry: Past and Present. Proceedings of the Thomas E. Starzl Festschrift (in press).

VIDEO PRESENTATIONS

1. Siegel CT, Loss GE, Grewal HP, Newell KA, **Woodle ES**, Cronin DC, Millis JM, Thistlethwaite JR, Bruce DS. Pancreas transplantation with portal venous and enteric exocrine drainage. American College of Surgeons, January, 1998.
2. Loss GE, Grewal HP, Siegel CT, Cronin DC, Newell KA, Bruce DS, **Woodle ES**, Thistlethwaite JR, Millis JM. Living donor liver transplantation. American College of Surgeons, January 1998.

PRESENTATIONS AT SCIENTIFIC MEETINGS

1. "Liver Blood Flow Determination By Dynamic Liver Imaging With Tc99--Galactosyl-Neoglycoalbumin: Comparison With The Continuous Infusion Indocyanine Green Technique." Society of University Surgeons, Resident's Meeting 45th Annual Meeting; University of Chicago, Chicago, IL, February 8, 1984.
2. "Tc99m-Galactosyl-Neoglycoalbumin Liver Imaging: Potential Application In Liver Transplantation." Society of Nuclear Medicine, 31st Annual Meeting; Los Angeles, CA, June 12, 1984.
3. "Tc99-M Galactosyl-Neoglycoalbumin Liver Imaging: A Means For Patient Selection In Liver Transplantation." Society of Nuclear Medicine, 9th Annual Western Region Meeting; Monterey, CA, October 13, 1984.
4. "Hepatocyte Receptor Concentration Measurements: An Objective Means For Evaluation Of Surgical Risk In Patients With Hepatocellular Disease." Sacramento Surgical Society Annual Meeting; Sacramento, CA, November 8, 1984.
5. "Tc99m-Galactosyl-Neoglycoalbumin Imaging In Liver Transplantation: Pre-Clinical And Clinical Studies." Society of Nuclear Medicine, Northern California Chapter, Spring Meeting; Sacramento, CA, March 23, 1985.
6. "Technetium-99m-Galactosyl-Neoglycoalbumin (Tc-Nga) Liver Imaging: Application In Liver Transplantation." Society of Nuclear Medicine, 32nd Annual Meeting; Houston, TX June 4, 1985.
7. "Receptor Binding Radiopharmaceuticals Labelled With Single Photon Emitting Radionuclides." Continuing Medical Education Course, Society of Nuclear Medicine, 32nd Annual Meeting; Houston, TX, June 4, 1985.
8. "Tc-Nga Imaging In Clinical Liver Transplantation." Sacramento Surgical Society Annual Meeting; Sacramento, CA, November 13, 1986.
9. "Anti-Human Cd3 Monoclonal Antibodies: Activation And Lymphokine Production Are Dependent On Antibody Isotype And Epitope Specificity". American Association of Immunology Annual Meeting; New Orleans, Louisiana, June 7, 1990.
10. "Anti-Human Cd3 Monoclonal Antibodies: An Approach Toward Optimization Of Okt3 Therapy". XIII Congress of the Transplantation Society; San Francisco, California, August 21, 1990.
11. "Reshaping Human Antibodies Using Okt3 Gene Segments: Successful Transfer Of Immune Modulating Properties And Idiotype Expression". American Society of Transplant Surgeons Annual Meeting, Chicago, Illinois, May 31, 1991.

12. "Fk 506: Reversal Of Humorally-Mediated Rejection Following Abo-Incompatible Liver Transplantation". First International Congress on FK 506, Pittsburgh, Pennsylvania, August 23, 1991.
13. "Humanized Okt3 Antibodies: In Vitro Analysis Of T Cell Activation And Suppression Properties And Idiotype." Second Basic Sciences Symposium of The Transplantation Society; Oxford University, Oxford, England, September 5, 1991.
14. "Recombinant Anti-Cd3 Antibodies: Immune Modulating Properties". Immunosuppressive Agents Workshop, Second Annual Basic Sciences Meeting of The Transplantation Society; Oxford University, Oxford, England, September 6, 1991.
15. "FK 506 Rescue Therapy For Acute Cellular And Humorally-Mediated Hepatic Allograft Rejection: An Aggressive Approach Yields Superior Results". American Society of Transplant Physicians, 12th Annual Meeting, Chicago, Illinois, May 26, 1992.
16. "Characterization Of The Response To FK 506 Rescue Therapy For Acute Hepatic Allograft Rejection." American Society of Transplant Physicians, 12th Annual Meeting, Chicago, Illinois, May 26, 1992.
17. "The Neurotoxicity Of FK 506 In Liver Transplant Recipients." International Liver Transplant Society, Minneapolis, Minnesota, September 16, 1992.
18. "Fk 506 Rescue Therapy: Early Conversion Improves Efficacy." International Liver Transplant Society, Minneapolis, Minnesota, September 16, 1992.
19. "Recurrent Rejection Following FK 506 Rescue Therapy For Acute Hepatic Allograft Rejection." International Liver Transplant Society, Minneapolis, Minnesota, September 17, 1992.
20. "FK 506 Rescue Therapy: The Rapidity Of Rejection Reversal Influences The Development Of CMV Disease And Recurrent Rejection." International Liver Transplant Society, Minneapolis, Minnesota, September 17, 1992.
21. "Intraoperative Balloon Angioplasty And Postoperative Endovascular Stenting In The Management Of AV Graft Thrombosis." A Symposium on Dialysis Access IV, Orlando, Florida, May 5, 1994.
22. "Iliac Vein Stenosis: The Lower Extremity Equivalent Of Subclavian Vein Stenosis." A Symposium on Dialysis Access IV, Orlando, Florida, May 5, 1994.
23. "Inhibition Of CD3-Dependent T-Cell Activation By A Mab Reactive Against The ? 3 Domain Of Human MHC Class I Molecules." American Society of Transplant Physicians, 13th Annual Meeting, Chicago, Illinois, May 16, 1994.

24. "Anti-CD3 Mab Therapy Induces Differential Effects On T Cell Subsets." American Society of Transplant Physicians, 13th Annual Meeting, Chicago, Illinois, May 16, 1994.
25. "Anti-CD3 Mab Induces Selective CD8+ T Cell Anergy In Vivo." First Annual Charles Huggins Research Conference, Chicago, Illinois, May 14, 1994.
26. "Induction Of Programmed Cell Death Via A Class I MHC-Mediated Pathway." Second Annual Charles Huggins Research Conference, Chicago, Illinois, May 6, 1995.
27. "Protocol Biopsies Provide Useful Information In FK 506 Treatment Of Refractory Renal Allograft Rejection." American Society of Transplant Physicians, 14th Annual Meeting, Chicago, Illinois, May 15, 1995.
28. "FK 506 Rescue Therapy For Renal Allograft Rejection: Experience With An Aggressive Approach." American Society of Transplant Physicians, 14th Annual Meeting, Chicago, Illinois, May 15, 1995.
29. "Okt3 Escalating Dose Regimens: Initial Experience." American Society of Transplant Physicians, 14th Annual Meeting, Chicago, Illinois, May 15, 1995.
30. "Induction Of Apoptosis In Human Lymphocyte By An Anti-Class I MHC ? 3-Domain Specific Monoclonal Antibody: Mimicking Of Veto Phenomena." American Society of Transplant Physicians, 14th Annual Meeting, Chicago, Illinois, May 17, 1995.
31. "The Histologic Response To Fk 506 Therapy For Refractory Renal Allograft Rejection." International Transplant Congress, Minneapolis, Minnesota, August 30, 1995.
32. "Class I Mhc-Induced Apoptosis." The Fourth Basic Sciences Symposium of the Transplantation Society. Noordwijkerhout, The Netherlands, September 19, 1995.
33. "A Multicenter Trial Of Tacrolimus Rescue Therapy In Renal Transplantation." 1995 Annual Meeting of the American Society of Nephrology, San Diego, California, November 7, 1995.
34. "Class I Mhc-Mediated Programmed Cell Death." American Heart Association 68th Annual Scientific Meeting, Anaheim, California, November 12, 1995.
35. "Tacrolimus Therapy For Refractory Acute Renal Allograft Rejection: A Prospective Multicenter Trial." 2nd International Conference on New Trends in Clinical and Experimental Immunosuppression, Geneva, Switzerland, February 16, 1996.

36. "Liver Transplantation In The First Three Months Of Life." American Society of Transplant Physicians, 15th Annual Meeting, Dallas, Texas, May 28, 1996.
37. "A Prospective Trial Of Corticosteroid Withdrawal Following Successful Tacrolimus Therapy For Refractory Renal Allograft Rejection." American Society of Transplant Physicians, 15th Annual Meeting, Dallas, Texas, May 29, 1996.
38. "A Prospective, Multicenter Trial Of FK 506 Therapy For Refractory Acute Renal Allograft Rejection." American Society of Transplant Physicians, 15th Annual Meeting, Dallas, Texas, May 29, 1996.
39. "Class I MHC Mediates Programmed Cell Death In A Fas-Independent Manner." American Society of Transplant Physicians, 15th Annual Meeting, Dallas, Texas, May 30, 1996.
40. "Liver Transplantation In The First Three Months Of Life." Second International Congress on Pediatric Transplantation, Paris, France, August 23, 1996.
41. "Class I MHC Mediates Programmed Cell Death In A Fas-Independent Manner." XVI International Congress of the Transplantation Society, Barcelona, Spain, August 29, 1996.
42. "A Prospective Trial Of Corticosteroid Withdrawal Following Successful Tacrolimus Therapy For Refractory Renal Allograft Rejection." XVI International Congress of the Transplantation Society, Barcelona, Spain, August 26, 1996.
43. "A Prospective, Multicenter Trial Of FK 506 (Tacrolimus) Therapy For Refractory Acute Renal Allograft Rejection." XVI International Congress of the Transplantation Society, Barcelona, Spain, August 26, 1996.
44. "Thymoglobulin Is More Effective Than ATGAM In Maintaining T Cell Depletion During And Following Therapy." American Society of Transplant Physicians, 16th Annual Meeting, Chicago, Illinois, May 12, 1997.
45. "Tacrolimus Therapy For Refractory Acute Renal Allograft Rejection: A Four Year Experience With An Aggressive Approach." International Congress on Immunosuppression, Orlando, Florida, December 11, 1997.
46. "Humanized, Nonmitogenic OKT3 Antibody, Huokt3v¹(Ala-Ala): Initial Clinical Experience." International Congress on Immunosuppression, Orlando, Florida, December 11, 1997.
47. "Construction Of A Single-Chain Antibody Derived From 5H7, A Mab Specific For A Death Signalling Domain Of Human Class I MHC." International Congress on Immunosuppression, Orlando, Florida, December 11, 1997.

48. "A Murine Transgenic Model Of Human Class I MHC-Mediated Programmed Cell Death." International Congress on Immunosuppression, Orlando, Florida, December 11, 1997.
49. "Corticosteroid Cessation 1 Week Following Renal Transplantation Using Tacrolimus (TAC)/Mycophenolate Mofetil (MMF)-Based Immunosuppression." International Congress on Immunosuppression, Orlando, Florida, December 11, 1997.
50. "Reversal Of Delayed Hyperacute Renal Allograft Rejection With A Tacrolimus-Based Therapeutic Regimen." International Congress on Immunosuppression, Orlando, Florida, December 11, 1997.
51. "Meta-Analysis Of Tacrolimus And Mycophenolate Refractory Rejection Trials In Renal Transplantation." International Congress on Immunosuppression, Orlando, Florida, December 11, 1997.
52. "Murine Transgenic Model Of Human Class I MHC PCD." American Society of Transplant Physicians, Chicago, Illinois, May 10, 1998.
53. "Early Steroid Cessation Under Tacrolimus/MMF Immunosuppression." American Society of Transplant Physicians, Chicago, Illinois, May 11, 1998.
54. "Thymoglobulin Randomized Rejection Transplant Trial: Twelve Month Results." American Society of Transplant Physicians, Chicago, Illinois, May 12, 1998.
55. "Twelve Month Intent To Treat Analysis Of The Double Blind, Randomized Multicenter Thymoglobulin Vs. Atgam Trial For The Treatment Of Acute Rejection Following Renal Transplantation." American Society of Transplant Surgeons, Chicago, Illinois, May 13, 1998.
56. "Twelve Month Intent To Treat Analysis Of The Double Blind Randomized Multicenter Thymoglobulin Versus Atgam Trial For The Treatment Of Acute Rejection Following Renal Transplantation." XVII World Congress of the Transplantation Society, Montreal, Canada, July 13, 1998.
57. "Corticosteroid Withdrawal In Renal Transplantation." XVII World Congress of the Transplantation Society, Montreal, Canada, July 14, 1998.
58. "A Murine Transgenic Model Of Human Class I MHC-Mediated Programmed Cell Death." XVII World Congress of the Transplantation Society, Montreal, Canada, July 16, 1998.
59. "Thymoglobulin Therapy For Acute Rejection Prevents Recurrent Rejection More Effectively Than Atgam In Renal Allograft Recipients." American Society of Nephrology, Philadelphia, Pennsylvania, October 26, 1998.

60. "The Phase III Randomized Multi-Center Trial Of Thymoglobulin Vs. Atgam In Kidney Transplant Recipients." Thymoglobulin Speaker Training Meeting, Carlsbad, California, April 10, 1999.
61. "Early Corticosteroid Withdrawal With Tacrolimus And Mycophenolate Mofetil (MMF) Immunosuppression In Renal Transplantation: Two Year Follow-Up Post Transplant Immunosuppression." New Paradigms, Minnesota Transplant Congress, Minneapolis, Minnesota, October 21, 1999.
62. "Biologic Behavior Of Carcinoid Tumors In Solid Organ Transplant Recipients: The Israel Penn International Transplant Tumor Registry Experience. Transplant 2001: A Transplant Odyssey, Istanbul, Turkey, August 21, 2001
63. "Kaposi's Sarcoma: Analysis Of The U.S. And International Experiences From The Israel Penn International Transplant Tumor Registry. Transplant 2001: A Transplant Odyssey, Istanbul, Turkey, August 21, 2001
64. "De Novo Breast Cancer In Renal Transplant Recipients". Second International Congress On Immunosuppression. San Diego, California, December 6, 2001.
65. "Steroid Withdrawal In Renal Transplantation: The Case For". Second International Congress on Immunosuppression. San Diego, California, December 6, 2001.

PRESENTATIONS BY TRAINEES

1. **Kopelan, A.** "Class I MHC antibodies induce programmed cell death via a pathway distinct from FAS." Charles Huggins Annual Research Conference, Chicago, Illinois, May 22, 1999.
2. **Kulkarni, S.** "Cell-mediated delivery of programmed cell death via class I MHC signaling." Sixth Basic Sciences Symposium of the Transplantation Society, Monterey Peninsula, California, August 28, 1999.
3. **Kopelan, A.** . "Class I MHC antibodies induce programmed cell death via a pathway distinct from FAS." Sixth Basic Sciences Symposium of the Transplantation Society, Monterey Peninsula, California, August 28, 1999.
4. **Mak G,** Buell JF, Aull M, Lo A, Hanaway MJ, Munda R, Alexander WJ, Fidler J, Rilo H, Hanto DH, Lo A, Hanaway M, Lewis D, First MR, Woodle ES. Donor Selection Algorithm for Non-Heart-beating Donors. Ohio Chapter, *American College of Surgeons, Spring Meeting* Dayton, Ohio May 11, 2001.
5. **Aull M,** Trofe J, Alloway RR, Hanaway M, First MR, Wagoner L, Beebe T, Woodle ES, Buell JF. Experience with 274 Cardiac Transplant Recipients Post-Transplant Lymphoproliferative Disorder: A Report from the Israel Penn Transplant Tumor Registry. *Transplant 2001*, Chicago, Illinois, May 14, 2001.
6. **Aull M,** First MR, Cardi M, Peddi VR, Weiskittel P, Berilla E, Meredith L, J Trofe, Zavala E, Alloway RR, Woodle ES, Buell JF. Long-term Graft Function in Renal Transplantation using Non-Heart-beating Donors. *Transplantation 2001*: Chicago, Illinois, May 15, 2001.

INVITED LECTURES

1. "Current Status of Transplantation of Abdominal Organs". Grand Rounds, Department of Surgery, Columbus-Cuneo-Cabrini Medical Center, Chicago, Illinois, June 7, 1989.
2. "Current State of Pancreas Transplantation". 4th Annual Critical Care Seminar, St. Catherine/St. Mary's Medical Center; Merrillville, Indiana, October 19, 1989.
3. "Portal Hypertension: Role of Liver Transplantation in the Management of Variceal Hemorrhage". Grand Rounds, Department of Surgery; Washington University School of Medicine, St. Louis, Missouri, November 28, 1990.
4. "Nonactivating Anti-Human CD3 Monoclonal Antibodies: An Approach Toward Optimizing OKT3 Therapy". Organ Transplantation Seminar; Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, December 7, 1990.
5. "Innovative Approaches in Liver Transplantation". Grand Rounds, Department of Surgery, St. John's Mercy Medical Center; St. Louis, Missouri, May 15, 1991.
6. "Anti-T Cell Receptor Monoclonal Antibodies: Clinical and Experimental Perspectives". Seattle Transplant Society Fall Meeting; Seattle, Washington, October 22, 1991.
7. "FK 506 Primary and Rescue Therapy in Kidney and Liver Transplantation". Loyola University Multidisciplinary Transplant Grand Rounds, Chicago, Illinois, February 28, 1995.
8. "Histology Definition of Rejection and Use as an End Point in Clinical Trials." The Efficacy Endpoints Conference: Acute Rejection in Kidney Transplantation, Chicago, Illinois, May 14, 1995.
9. "Intraoperative Balloon Angioplasty and Postoperative Endovascular Stenting in the Management of AV Graft Stenosis." Dialysis Access Symposium, Chicago, Illinois, May 25, 1995.
10. "Tacrolimus Therapy in Kidney and Liver Transplantation." Fujisawa Canada Medical Science Liaison Training Program, San Diego, California, November 8-9, 1995.
11. "Current Immunosuppressive Medications: Transplantation and Beyond." Advances in the Treatment of Liver Disease, Chicago, Illinois, March 9, 1996.

12. "Tacrolimus Therapy for Prevention and Treatment of Cell- and Antibody-Mediated Rejection of Solid Organ Allografts." Fujisawa Research Group, Deerfield, Illinois, March 25, 1996.
13. "Perspectives on the Use of Tacrolimus in Maintenance and Rejection Therapy in Liver and Kidney Transplantation." Argentine Multicenter Tacrolimus Study Group, Buenos Aires, Argentina, April 19, 1996.
14. "Surgical Versus Radiologic Intervention for AV Graft Thrombosis/Stenosis: Cost and Outcome." Fifth Biannual Symposium for Vascular Access for Hemodialysis V, Tucson, Arizona, May 9, 1996.
15. "New Biologic Immunosuppressive Agents." ASTP Symposium on Transplantation Medicine, St. Louis, Missouri, July 28, 1996.
16. "Tacrolimus Therapy for Prevention and Treatment of Renal Allograft Rejection." Eastern Canadian Advisory Group on Tacrolimus Therapy, Montreal, Canada, September 18, 1996.
17. "Tacrolimus Therapy for Prevention and Treatment of Renal Allograft Rejection." Central Canadian Advisory Group on Tacrolimus Therapy, Toronto, Canada, September 19, 1996.
18. "Tacrolimus Therapy for Prevention and Treatment of Renal Allograft Rejection." Western Canadian Advisory Group on Tacrolimus Therapy, Vancouver, Canada, September 21, 1996.
19. "Tacrolimus Therapy in Renal Transplantation." Eastern United States Advisory Board on Tacrolimus Therapy, Washington, D.C., October 6, 1996.
20. "New Immunosuppressive Agents: Tacrolimus." Interdisciplinary Conference on Management Issues in Renal Transplantation, Delavan, Wisconsin, October 11, 1996.
21. "Transplant Immunobiology." Improving Transplant Patient Outcomes: A Conference for Transplant Coordinators, Chicago, Illinois, October 18, 1996.
22. "Tacrolimus Therapy for Renal Allograft Rejection." Consensus Panel for Guidelines on Tacrolimus Therapy in Renal Transplantation, Chicago, Illinois, October 18, 1996.
23. "Kidney/Pancreas and Pancreas Transplantation: Benefits and Complications." National Kidney Foundation 46th Annual Meeting, New Orleans, Louisiana, November 2, 1996.

24. "Pivotal Trials of Tacrolimus Therapy for Prevention of Renal Allograft Rejection." Western United States Advisory Board on Tacrolimus Therapy, Los Angeles, California, November 21, 1996.
25. "Death Signaling Via Class I MHC." University of Chicago, Section of Nephrology Research Seminar, December 4, 1996.
26. "Mycophenolate, Sirolimus, and Tacrolimus Therapy in Renal Transplantation." Henri Bismuth Transplant Fellows Symposium, Phoenix, Arizona, December 12, 1996.
27. "Mycophenolate, Sirolimus, and Tacrolimus Immunosuppression in Renal Transplantation X Who, When, and Where." University of Maryland, January 7, 1997.
28. "New Approaches for Prevention and Treatment of Renal Allograft Rejection," Transplant Seminar, Columbia University College of Physicians and Surgeons, New York, New York, February 4, 1997.
29. "Prevention and Treatment of Renal Allograft Rejection with Tacrolimus." Midwest United States Advisory Board on Tacrolimus Therapy, Chicago, Illinois, February 19, 1997.
30. "Humanized, Nonmitogenic OKT3 and Tacrolimus in the Treatment of Renal Allograft Rejection." Transplant Grand Rounds, Washington Hospital Medical Center, Washington, D.C., February 26, 1997.
31. "Tacrolimus Therapy in Renal Transplantation: From Terminal Treatment to Primary Prevention." Asia Pacific Forum in Nephrology V, Hayman Island, Great Barrier Reef, Queensland, Australia, March 9, 1997.
32. "Evolution of Tacrolimus Therapy in Renal Transplantation." Queensland Advisory Group on Tacrolimus Therapy, Brisbane, Queensland, Australia, March 10, 1997.
33. "Multicenter Trials of Tacrolimus Therapy in Renal Transplantation." South Australia Advisory Board on Tacrolimus Therapy in Renal Transplantation, Melbourne, Australia, March 11, 1997.
34. "Current and Future Perspectives in Tacrolimus-Based Immunosuppression." New South Wales Advisory Board on Tacrolimus Therapy, Sydney, Australia, March 12, 1997.
35. "Tacrolimus Primary and Rescue Therapy for Cellular and Antibody-Mediated Rejection." Advisory Panel of Tacrolimus Therapy in Renal Transplantation, Dallas, Texas, March 27, 1997.

36. "Clinical Trials of Tacrolimus in Renal Transplantation." National Kidney Foundation Sixth Annual Clinical Nephrology Meeting, Dallas, Texas, April 17, 1997.
37. "Tacrolimus Therapy in Renal Transplantation." Eastern United States Advisory Board on Tacrolimus Therapy, Boston, Massachusetts, May 29, 1997.
38. "Transplant Immunobiology." Fujisawa National Training Seminar, Deerfield, Illinois, June 2, 1997.
39. "Transplant Immunosuppression." Fujisawa National Training Seminar, Deerfield, Illinois, June 3, 1997.
40. "Tacrolimus Primary and Rejection Therapy in Liver Transplantation." Argentine National Symposium on Tacrolimus, Buenos Aires, Argentina, June 24, 1997.
41. "Experience with Tacrolimus Immunosuppression in Solid Organ Transplantation at the University of Chicago." Fujisawa Grand Rounds, Deerfield, Illinois, July 8, 1997.
42. "Early Corticosteroid Discontinuation and Tacrolimus/Mycophenolate Mofetil-based Immunosuppression in Renal Transplantation: A Pilot Study." Fujisawa Grand Rounds, Deerfield, Illinois, July 8, 1997.
43. "Investigational Biologic Immunosuppressive Agents." ASTP Symposium on Transplantation for Fellows, St. Louis, Missouri, July 17, 1997.
44. "Tacrolimus Therapy for Renal Allograft Rejection." Hong Kong Society of Transplantation Symposium on Immunosuppression in Solid Organ Transplantation, Hong Kong, China, September 19, 1997.
45. "Optimal Immunosuppression in Kidney and Liver Transplantation." Transplantation Society of the Republic of China Symposium on Organ Transplantation, Taipei, Taiwan, September 20, 1997.
46. "New Trends in Immunosuppression in Organ Transplantation." Grand Rounds, Yonsei University, Department of Surgery, Seoul, South Korea, September 23, 1997.
47. "Tacrolimus Therapy in Solid Organ Transplantation." University of Pennsylvania Transplant Seminar, Philadelphia, Pennsylvania, October 8, 1997.
48. "Design and Execution of Clinical Trials in Transplantation." Professor Christoph E. Broelsch Transplant Fellows Symposium, Scottsdale, Arizona, November 7, 1997.

49. "Delayed Hyperacute Renal Allograft Rejection: Tacrolimus X Based Therapy." Professor Christoph E. Broelsch Transplant Fellows Symposium, Scottsdale, Arizona, November 8, 1997.
50. "Medical and Ethical Considerations in Living Donor Renal Kidney Exchange Programs." New England Organ Bank, Boston, Massachusetts, December 4, 1997.
51. "University of Chicago Experience with Tacrolimus Primary and Rescue Therapy." Vanderbilt University Transplant Seminar, Nashville, Tennessee, December 5, 1997.
52. "Overview on the Use of Tacrolimus as Rescue Therapy in Kidney Transplantation." International Congress on Immunosuppression, Orlando, Florida, December 10, 1997.
53. "Steroid Withdrawal in Renal Transplantation." ProGraf Steroid Withdrawal Study Group Investigator's Meeting, Boca Raton, Florida, March 7, 1998.
54. "Steroid Withdrawal Under Modern Immunosuppressive Therapy." Saint Barnabas Health Care System Transplant Grand Rounds, March 10, 1998, Livingston, New Jersey.
55. "Corticosteroid Withdrawal Under Modern Immunosuppressive Therapy." 1998 Transplant Institute Meeting, March 12, 1998, San Diego, California.
56. "Pancreas Transplantation: Advances in Operation Techniques and Immunosuppressive Therapy." 1998 Transplant Institute Meeting, March 12, 1998, San Diego, California.
57. "Role of Compliance in Modern Immunosuppressive Therapy." First International Symposium on Transplant Recipient Compliance, April 3, 1998, Arlington, Virginia.
58. "Tacrolimus Therapy in Renal Transplantation: State of the Art." Brigham and Women's Hospital, Harvard University Medical School, Boston, Massachusetts, June 1, 1998.
59. "Corticosteroid Withdrawal in Renal Transplantation: State of the Art." Deaconess and Beth Israel Hospital, Harvard University Medical School, Boston, Massachusetts, June 2, 1998.
60. "Thymoglobulin Therapy for Acute Renal Allograft Rejection." Optimal Immunosuppressive Strategies Seminar, San Diego, California, June 25, 1998.

61. "Tacrolimus-Based Immunosuppression in Renal Transplantation." Second Annual Congress of the Mexican Transplantation Society, Merida, Mexico, June 26, 1998.
62. "Immunosuppressive Strategies to Rescue Rejections." Abdominal Transplantation at the Millennium, University of Washington, Seattle, Washington, September 11, 1998.
63. "New Issues in Immunosuppression." International Transplant Nurses Society, Portland, Oregon, September 11, 1998.
64. "Should Corticosteroids Be Used to Treat Rejection?" ASTP/ASTS Interdisciplinary Conference on Corticosteroid Withdrawal, St. Louis, Missouri, September 17, 1998.
65. "Panel Reactive Antibody Testing in Renal Transplantation." Midwest Kidney-Pancreas Advisory Board Meeting, University of Wisconsin, Kohler, Wisconsin, September 18, 1998.
66. "Living Donor Kidney Exchange Programs." American Society of Nephrology, 1998 Annual Meeting, Philadelphia, Pennsylvania, October 26, 1998.
67. "Thymoglobulin May be More Efficacious Than Atgam for Reducing Recurrent Acute Renal Allograft Rejection: Results of the U.S. Multicenter Double Blinded Comparative Trial." American Society of Nephrology, 1998 Annual Meeting, Philadelphia, Pennsylvania, October 27, 1998.
68. "Tacrolimus: Optimal Use and Potential for Steroid Withdrawal." Advances in Immunosuppressive Therapy Annual Transplant Symposium, Somerset, New Jersey, November 6, 1998.
69. "Routine Immunosuppression: Neoral vs. FK 506." American Association for the Study of Liver Disease/ American Hepato-Biliary Association for Hepatobiliary Surgery, Chicago, Illinois, November 7, 1998.
70. "Corticosteroid Withdrawal in Renal Transplantation: State of the Art." Philadelphia Transplant Society, Philadelphia, Pennsylvania, November 10, 1998.
71. "Tacrolimus/Mycophenolate Mofetil-Based Immunosuppression." University of Pennsylvania Transplant Grand Rounds, Philadelphia, Pennsylvania, November 11, 1998.
72. "Paired Living Donors: Kidney Exchange Program." Innovative Approaches to the Transplant Organ Shortage: A Transplant Conference, Scottsdale, Arizona, November 16, 1998.

73. "Why Patients Do Not Adhere to Medications: Results of a Survey." Immunosuppression Conference in Organ Transplantation: Patient Access to Long-Term Care, Philadelphia, Pennsylvania, December 4, 1998.
74. "U.S. Study Comparing Tacrolimus and Cyclosporine Microemulsion-based Regimens with or without MMF." New Horizons in Kidney Transplantation, Lisbon, Portugal, March 9, 1999.
75. "Corticosteroid Withdrawal under Tacrolimus Therapy." New Horizons in Kidney Transplantation, Lisbon, Portugal, March 9, 1999.
76. "Corticosteroid Withdrawal in Transplantation: State of the Art." Ochsner Clinic, New Orleans, Louisiana, May 11, 1999.
77. "Approaches for Developing New Immunosuppressive Regimens." Texas Transplantation Society annual meeting, Galveston, Texas, June 27, 1999.
78. "Corticosteroid Withdrawal: State of the Art." Georgetown University, Washington, D.C., June 30, 1999.
79. "New Immunosuppressive Regimes for Corticosteroid Withdrawal." Medical College of Georgia, Atlanta, Georgia, November 10, 1999.
80. "Abolition of Corticosteroid Therapy in Transplantation: A Goal for the Future." Emory University, School of Medicine, Atlanta, Georgia, November 1, 1999.
81. "Sirolimus Therapy-Renal Transplantation." Duke University Medical School, Durham, North Carolina, December 7, 1999.
82. "Sirolimus Therapy – Renal Transplantation." University of Kentucky, School of Medicine, Lexington, Kentucky, December 15, 1999.
83. "Clinical Trial Design Strategies for Corticosteroid Withdrawal/Avoidance Under Sirolimus." Wyeth-Ayerst Corporate Development Seminars, Radnor, Pennsylvania, January 16, 2000.
84. "Corticosteroid Withdrawal: Elements of Clinical Trial Design." Wyeth-Ayerst Multicenter Trial Design Advisory Meeting, Atlanta, Georgia, February 9, 2000.
85. "Kidney/Pancreas Transplantation." LifeCenter Continuing Education Seminar, Cincinnati, Ohio, February 23, 2000.
86. "Technical Perspectives – Liver Transplantation and Liver Surgery." Trauma 2000 Symposium, Tyler, Texas, March 10, 2000.

87. "Future Directions in Transplantation-Should Calcineurin Phosphatase Inhibitors or Corticosteroids Be Removed From Immunosuppressive Regimens?" Third Congress of the Transplantation Society of the Southern Cone/Third Congress of the Uruguayan Society of Transplantation, Punta Del Este, Uruguay, March 15, 2000.
88. "Corticosteroid Withdrawal in Transplantation: State of the Art." Third Congress of the Transplantation Society of the Southern Cone/Third Congress of the Uruguayan Society of Transplantation, Punta Del Este, Uruguay, March 15, 2000.
89. "Cancer in Transplantation." Third Congress of the Transplantation Society of the Southern Cone/Third Congress of the Uruguayan Society of Transplantation, Punta Del Este, Uruguay, March 16, 2000.
90. "Corticosteroid Withdrawal in Cardiac Transplantation." Third Congress of the Transplantation Society of the Southern Cone/Third Congress of the Uruguayan Society of Transplantation, Punta Del Este, Uruguay, March 16, 2000.
91. "Elimination of Calcineurin Phosphatase Inhibitors or Corticosteroids from Immunosuppressive Therapy: Which should go first?" Transplant Grand Rounds, University of Florida, Gainesville, Florida, April 25, 2000.
92. "Pancreas Transplantation Update" Miami Valley Hospital Transplant Seminar, Dayton, Ohio, May 3, 2000.
93. "Steroid Avoidance at the University of Cincinnati" Miami Valley Hospital Transplant Seminar, Dayton, Ohio, May 3, 2000.
94. "Pancreas Transplantation Update" Greater Cincinnati Transplant Dinner Conference, Cincinnati, Ohio, May 24, 2000.
95. "Steroid Avoidance at the University of Cincinnati" Greater Cincinnati Transplant Dinner Conference, Cincinnati, Ohio, May 24, 2000.
96. "Tacrolimus-Based Immunosuppressive Regimens in Renal Transplantation", 6th Annual Meeting of the Israel Transplantation Society, Jerusalem, Israel, May 31, 2000.
97. "The Israel Penn International Transplant Tumor Registry: From Denver to Cincinnati" Thomas E. Starzl Festschrift, University of Pittsburgh, Pennsylvania April 28, 2001.
98. "The Road toward Steroid-Free Immunosuppression", Frank D. Stuart Festschrift, Case Western University, Chicago Illinois, May 15, 2001.
99. "Antilymphocyte Antibodies: Role in Steroid Sparing Regimes", Canadian Transplant Forum on Long Term Immunosuppression Management, Ottawa, Canada, November 2, 2001.

100. "Immunosuppression: The Changing Face of Transplantation", University of Cincinnati Transplant Grand Rounds, Cincinnati, Ohio, October 31, 2001.
101. "Evolution of Kidney Exchange Programs in Kidney Transplantation", Society for Transplant Social Workers, Sixteenth Annual Conference, Santa Fe, New Mexico, November 7, 2001.
102. "Islet Transplantation at the University of Cincinnati," American Diabetes Association Convention, Cincinnati, Ohio, November 11, 2001.
103. "Solid Organ Donors with a History of Cancer: Risk of Malignancy Transmission. 10th Swiss Transplant Meeting. Interlaken, Switzerland, January 25-26, 2002.